RDsaúde

(Convenience Translation into English from the Original Previously Issued in Portuguese)

Juntos por uma sociedade mais saudável

Raia Drogasil S.A.

Individual and Consolidated
Interim Financial Information
At September 30, 2026





Raia DROGASIL

stix HEALTHBIT uma empresa RDsaúde CUCO HEALTH impulso soluções de mídia RDsaúde amplimed

Individual and Consolidated Interim Financial Information At September 30, 2026

(Convenience Translation into English from the Original Previously Issued in Portuguese)

Contents

Comments on Company performance 4

Individual and consolidated interim financial information

Balance sheets 19

Statements of income 20

Statements of comprehensive income 21

Statements of changes in equity 22

Statements of cash flows 23

Statements of value added 24

Notes to the individual and consolidated interim financial information

Comments on Company performance 4

1. Operations 26
2. Presentation of quarterly information 28
3. New accounting procedures, amendments to and interpretations of standards 29
4. Material accounting practices 29
5. Cash and cash equivalents 30
6. Financial investments 30
7. Trade receivables 31
8. Inventories 32
9. Recoverable taxes 33
10. Investments 34
11. Property, plant and equipment 39
12. Intangible assets 43
13. Employee benefits 47
14. Suppliers 47

15. Liabilities with senior shareholders 48
16. Borrowings and debentures 49
17. Leases....54
18. Provision for contingencies and judicial deposits....58
19. Income tax and social contribution 60
20. Earnings per share 62
21. Equity 63
22. Net sales revenue 66
23. Information on the nature of expenses recognized in the statement of income 67
24. Other operating income or expenses, net....68
25. Finance income (costs) 69
26. Financial instruments and risk management policy 70
27. Transactions with related parties 74
28. Insurance coverage....77
29. Non-cash transactions 77
30. Discontinued operations – Sale of 4Bio....77

Opinions and representations

Independent Auditor's Report on the Interim Financial Information 80
Comments on Business Projections Performance....82
Supervisory Board’s Opinion 83
Officers' Representation on the Quarterly Information....84
Officers' Representation on the Independent Auditor's Report 85



Convenience Translation into English from the Original Previously Issued in Portuguese)

Comments on Company performance

São Paulo, November 03, 2026. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 3rd quarter of 2026 (3Q26). The Company's parent company and consolidated financial statements for the periods ended September 30, 2026 and 2025 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same
period of the previous year.

IFRS 16: Our financial statements are prepared in accordance with IFRS 16. To better reflect the economic reality of the business, the figures presented in this report consider the pre-IFRS 16 standard with a reconciliation available in a dedicated section of this document.

HIGHLIGHTS:

Organic expansion maintains a strong pace
3.770 units in operation with 92 openings and 9 closures in the quarter;
333 LTM gross openings, reiterating the guidance of 330-350 gross openings in 2026;

Sales growth remains strong and above inflation
Gross revenue of R$ 13.2 billion, +16.0% growth and a R$ 1.8 billion increment;
MSSS growth of +8.4%, a real growth +5.6 pp above the annual CMED adjustment;

Market share gains in every region
19.1% national share, a +1.1 pp increase with gains in every region;

Digital sales combine scale and omnichannel leadership
Gross revenue of R$ 3.8 billion, +27.2% growth and retail penetration of 29.4%;

Growth with resilient margins
Adjusted EBITDA of R$ 1.0 billion, +14.7% & margin of 7.8% (-0.1 pp);
Adjusted net income of R$ 439 MM, +9.2% (including 4Bio) & margin of 3.3% (-0.2 pp);
Excluding 4Bio impacts, net income growth of +20.1% & margin expansion of +0.1 pp;

Low leverage with cash generation
R$ 160 MM positive free cash flow and R$ 57 MM total cash generation;
0.8x ND/EBITDA, a 0.3x reduction.

RADL3
R$ 15.22/share
Closing Oct 30, 2026

MARKET CAP
R$ 26.7 billion

NUMBER OF SHARES
1,752,367,344
All ordinary

IR TEAM:
Flávio Correia
André Stolfi
Victor Torres
Felipe Correa


ir.rdsaude.com.br
ri@rdsaude.com.br

New consolidated summary (ex-4Bio)

In R$ thousands	3Q25	4Q25	1Q26	2Q26	3Q26
# of pharmacies	**3,453**	**3,547**	**3,614**	**3,687**	**3,770**
Organic openings	88	97	68	76	92
Closures	(6)	(3)	(1)	(3)	(9)
Headcount (EoP)	69,860	73,388	75,190	75,594	77,428
Pharmacist count (EoP)	13,981	14,377	14,965	15,199	15,478
# of tickets (thousands)	111,543	114,731	111,849	119,305	119,277
# of active customers (MM)	51.0	51.7	52.3	52.8	53.3
Gross revenue	**11,347,942**	**12,186,767**	**11,979,521**	**12,777,743**	**13,163,282**
Growth (YoY)	+15.5%	+22.3%	+20.4%	+18.3%	+16.0%
Gross profit	3,257,291	3,508,601	3,392,636	3,696,071	3,795,614
% of gross revenue	28.7%	28.8%	28.3%	28.9%	28.8%
Adjusted EBITDA	**892,592**	**924,318**	**820,786**	**1,017,348**	**1,023,739**
% of gross revenue	7.9%	7.6%	6.9%	8.0%	7.8%
Adj. net income (w/ 4Bio)	**401,986**	**361,654**	**299,752**	**432,729**	**439,124**
% of gross revenue	3.5%	3.0%	2.5%	3.4%	3.3%
Free cash flow	**615,609**	**(466,520)**	**284,869**	**549,989**	**160,161**


STORE DEVELOPMENT

Pharmacy count



	3Q25	4Q25	1Q26	2Q26	3Q26	LTM
Gross openings	**+88**	**+97**	**+68**	**+76**	**+92**	**+333**
Closures	-6	-3	-1	-3	-9	-16
- Maturing	-	*-1*	-	-	*-2*	*-3*
- Mature	*-6*	*-2*	*-1*	*-3*	*-7*	*-13*
Net openings	**+82**	**+94**	**+67**	**+73**	**+83**	**+317**

Pharmacy portfolio by age




We ended 3Q26 with a total of 3,770 pharmacies in operation, opening 92 new units in the quarter and 333 LTM. We reiterate our guidance of 330-350 gross openings for 2026.


We closed 9 units in 3Q26 totaling 16 LTM, with only 3 still in the maturation process. This equates to less than 1% of the LTM openings, highlighting the precision of our expansion process. The remaining 13 LTM closures were of mature units with an average of 11 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC.

At the end of 3Q26, a total of 25.2% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.


Number of cities with pharmacies



Pharmacies by region



Pharmacies by format




Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 697 cities in every state, +44 vs. the prior year, a unique capillarity in Brazilian retail under direct management.

We maintained a consistent expansion pace in São Paulo, our largest market, sustaining 35% of the LTM expansion plan. Even with our broad presence in the state, we continue to identify meaningful opportunities and see solid performance from newly opened stores, reinforcing the potential to grow profitably across the country.


Lastly, the IRR of new pharmacies continues sustaining record levels, reflecting greater expansion assertiveness supported by the recent efficiency gains in operations, the omnichannel performance, the emerging GLP-1 market, among other factors.

Geographic presence



Retail Market Share

Quarterly share, customer prices, sell-out + sell-in



Source: IQVIA. Southeast excludes SP.

Our 3.8 thousand pharmacies are present in every state in the country and supported directly by an integrated network of 16 distribution centers. This logistics grid allows us to serve more than 80% of our locations daily with lead times of up to 24 hours. As a result, we sustain high service levels, optimize working capital, and strengthen operational efficiency, establishing a significant competitive advantage.

Our national market share reached 19.1% in the quarter, a solid gain of +1.1 pp vs. the prior year. In addition, we recorded relevant gains across all regions, underscoring our competitive strength in diverse contexts and markets. Market shares reached 33.0% in São Paulo (+1.1 pp), 14.3% in the Southeast (+1.1 pp), 24.8% in the Midwest (+1.9 pp), 11.5% in the South (+0.5 pp), 14.2% in the Northeast (+1.3 pp), and 12.1% in the North (+1.0 pp).


The +1.1 pp gain in national market share includes the sequential stabilization of GLP-1 products near a 12% share of retail sales. Excluding GLP-1 items, our total market share gain continued robust, a little below +1 pp, with gains across every region.

DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT

We continued to advance our digital strategy, further strengthening our relationship with the customer. In the last 12 months, we recorded over 1 billion visits across our digital channels, an impactful audience that enhances our role in promoting health. In addition, digitalization increases spending per customer, with digitally engaged loyal customers spending 30% more than the average loyal customer.


Digital sales and penetration

R$ millions, % of retail gross revenue



Digital channel mix


% of quarterly digital sales



80 NPS
App rating
R$ 14.9 B
LTM digital sales

Delivery mix

% of quarterly digital sales



83 NPS
Delivery rating
>1 billion visits
Via apps and website LTM

We recorded R$ 3.8 billion in digital channel gross revenue in 3Q26, a growth of +27% vs. the prior year. The share of these channels was 29.4% of retail sales, an increase of +2.7 pp.

The share of digital channels within sales recorded a sequential decrease of -1.6 pp, entirely driven by the new pricing policy that now offers the same GLP-1 discounts in-store, previously exclusive to digital purchases. As a result, the participation of physical channels in this product category increased from 25% in 2Q26 to 40% in October 2026, once again showcasing the importance of the physical pharmacy presence in the customer's health journey. Tthe remaining product categories continued gaining digital penetration.


Among our digital channels, we highlight the intense use of our apps, in which our customers enjoy the best mobile experience specialized in omnichannel health and wellness journeys. Digital sales through apps increased +30% vs. the prior year, with a dominant 83% share of digital sales in the quarter.


This evolution in customer digitalization, leveraging our modern and proprietary channels, reflects the ongoing improvement of our mobile experience and a more complete, fully omnichannel health journey. It enhances the capillarity of our store network, which has 95% of the A-Class population within a 1.5 km radius and enables 96% of digital orders to be delivered or picked up in less than 60 minutes with high economic efficiency.

The customer omnichannel experience is strengthened by Stix, our loyalty ecosystem that joins over 9,000 points of sale from the brands Drogasil, Raia, Pão de Açúcar, Extra, Shell and Petlove, in addition to the financial partners Itaú and Livelo. In July 2026, RD Saúde acquired from GPA the remaining 67% of the capital of Stix, taking leadership of the coalition that benefitted 15.6 million active customers, a 26% increase vs. the prior year, of which 6.8 million interacted with 2 or more of the partners.

Lastly, we continued to strengthen the role of our pharmacies in the customer's integral health journey, positioning our locations as health hubs within the communities we serve and expanding engagement through pharmaceutical services. We now have 3.2 thousand units with *Mais Saúde* hubs and their expanded services portfolio, in addition to 462 units enabled for vaccination. In 3Q26, more than 2.2 million pharmaceutical services were performed, including CATs (clinical analysis tests), vaccinations, and other services, recording an NPS superior to the pharmacy average of 91.


GROSS REVENUES






We ended 3Q26 with R$ 13,163 million in gross revenue, a 16.0% growth vs. the prior year and a relevant increment of R$ 1.8 billion, in a quarter with a negative calendar effect of 0.3 pp. This pace of growth is in-line with expectations given the stabilization since 4Q25 of GLP-1 items within the products mix. Furthermore, the incorporation of Stix in 3Q26 contributed +0.4 pp to the quarter's consolidated growth.

We sustained a robust growth across all categories. Branded Rx grew +19.8% in the quarter, still growing at double-digit rates when excluding GLP-1 products. We highlight that the recent launching of new GLP-1 semaglutide products improves customer accessibility, with the additional unit volume offsetting the relevant reduction in average prices, still sustaining revenue. We note that we still observe limited supply from the industry for these new brands. Meanwhile, the other categories displayed positive performance: Generics grew +11.7%, HPC +13.4%,.and OTC +10.8%, despite a milder winter, above-average rain in the South and Southeast and weaker demand for seasonal items.



Finally, we recorded average same-store sales growth of +10.1% in 3Q26. Among mature stores, which completed the full 3-year ramp-up, we posted an average growth of +8.4%, a pace 5.6 pp above the 2.8% CMED price adjustment authorized in 2026 and 3.8 pp above the LTM CPI. We highlight that, aligned with the market share gains, mature-store performance was strong in all regions, underscoring the elevated competitiveness of our brands within the different market environments.

GROSS PROFIT




Gross profit totaled R$ 3,795.6 million in 3Q26, equivalent to a gross margin of 28.8% with a 0.1 pp expansion vs. the prior year. The incorporation of Stix in 3Q26 contributed with .2 pp.

We recorded a 0.2 pp pressure from the NPV adjustments, reflecting the lower Selic interest rate, in addition to pressures from the greater mix of GLP-1 products and of digital channels. These pressures were offset by lower inventory losses and from commercial gains.


SELLING EXPENSES

Selling expenses totaled R$ 2,429.0 million in 3Q26, equivalent to 18.5% of gross revenue, a 0.3 pp pressure vs. the prior year. There we no material effects from the incorporation of Stix.

This quarter still includes the 0.5 pp pressure stemming from the 4Q25 investments into our Employee Value Proposition (EVP), in addition to lesser pressures from expenses with security services and last mile deliveries. These were partly offset by dilutions in rentals and payment processing fees, in addition to an important operating leverage derived from the strong mature-store sales growth above inflation.



GENERAL & ADMINISTRATIVE EXPENSES




RD Saúde's corporate structure continued delivering operating leverage. The incorporation of Stix in 3Q26 led to general and administrative expenses totaling R$ 342.9 million, corresponding to 2.6% of gross revenue, stable vs. the prior year. Without Stix, G&A expenses would represent 2.4% of gross revenue, a 0.2 pp dilution.

We highlight that the sequential increase in G&A expenses is expected given the provision for the yearly salary adjustment in the state of São Paulo, where our headquarters are located.


EBITDA

We recorded an adjusted EBITDA of R$ 1,023.7 million in 3Q26, a 14.7% expansion vs. the prior year. The EBITDA margin was of 7.8% of gross revenue, a 0.1 pp contraction, which in this quarter still includes the effects of the investments into our employee value proposition (EVP).

The incorporation of Stix in 3Q26 contributed with 0.1 pp to the quarter's EBITDA margin.



DEPRECIATION, NET FINANCIAL EXPENSES AND EBT




Adjusted depreciation expenses totaled R$ 300.0 million in 3Q26, equivalent to 2.3% of gross revenue, stable vs. the prior year.

Adjusted net financial expenses totaled R$ 174.9 million in 3Q26, representing 1.3% of gross revenue, a strong dilution of 0.6 pp vs. the prior year. This dilution includes 0.4 pp stemming from the impacts of a lower average Selic rate upon financial liabilities, resulting in R$ 119.9 million in net financial expenses (0.9% of gross revenue). Additionally, we recorded a financial revenue of R$ 22.7 million from the sale of 4Bio.

We also recorded a 0.2 pp dilution from the non-cash NPV adjustment, equivalent to R$ 54.9 million (0.4% of gross revenue).

Lastly, we recorded an increase of 31.0% in our adjusted EBT vs. the prior year, totaling R$ 547.6 million in 3Q26. This was equivalent to 4.2% of gross revenue, a 0.5 pp expansion.

INCOME TAXES AND NET INCOME



We provisioned a total of R$ 108.5 million in adjusted income tax in 3Q26, 0.8% of gross revenue, an increase of 0.2 pp vs. the prior year. The effective tax rate was 19.8% of EBT, an increase of 2.8 pp driven by the lower proportion of interest on equity provisioned in the quarter. The YTD recurring effective tax rate was of 19.4%.

Adjusted consolidated net income was of R$ 439.1 million in 3Q26, with a net margin of 3.3% of gross revenue. There was no material effect from the incorporation of Stix.

When excluding the effects of 4Bio, both its operational profit in 3Q25 (R$ 55.2 million, which included non-recurring tax gains) and the financial revenue in 3Q26 stemming from its sale (R$ 22.7 million), we recorded a net margin of 3.2% in this quarter with a 0.1 pp expansion and an earnings growth of 20.1%. These earnings and margin improvements underscore the resilient aspect of the business, which boasts a solid track record in navigating different economic and political backdrops. We also highlight that these earnings improvements will continue to be complemented by the financial revenue stemming from the sale of 4Bio.

EBITDA & NET INCOME RECONCILIATION AND NON-RECURRING RESULTS


Adjusted EBITDA & Net Income Reconciliation (R$ millions)	3Q25	3Q26
Net income	**476.1**	**426.9**
Results of discontinued operations (4Bio)	(92.1)	0.0
Income tax	90.2	102.2
Equity equivalence	(1.0)	1.3
Financial result	210.9	174.9
EBIT (ex-4Bio)	**684.0**	**705.2**
Depreciation and amortization	264.8	300.0
EBITDA (ex-4Bio)	**948.8**	**1,005.2**
Asset write-offs	1.3	1.5
Social investments and donations	1.6	0.6
Tax effects from previous years	(15.6)	13.0
Other non-recurring/non-operating effects	(43.6)	3.4
Adjusted EBITDA (ex-4Bio)	**892.6**	**1,023.7**
Net income	**476.1**	**426.9**
Net non-rec. effects of discont. operations (4Bio)	(37.0)	-
Non-recurring EBITDA effects	(56.2)	18.6
Non-rec. effects of cont. op. on income taxes (34%)	19.1	(6.3)
Adjusted net income	**402.0**	**439.1**

Within our EBITDA, we recorded R$ 18.6 million in net non-recurring expenses in the 3Q26. This includes expenses of R$ 1.5 million in asset write-offs, R$ 0.6 million in social investments & donations, R$ 13.0 million related to tax effects of previous years and R$ 3.4 million in other non-recurring effects. In net income, we recorded a reduction of R$ 6.3 million in income taxes from the non-recurring effects.

CASH CYCLE

We recorded a cash cycle improvement of 2.4 days vs. the prior year, totaling 54.2 days in 3Q26. This is already adjusted for discounted receivables, forward payments to suppliers, and also includes the positive effects derived from the end of the ICMS-ST tax regime in the state of São Paulo.

We recorded increases of 1.4 days in inventories, due to the lower sales of seasonal items, and of 0.6 days in receivables, more than offset by an increase of 4.4 days in suppliers.



* Adjusted for discounted receivables & advanced payments to suppliers.

CASH FLOW

Cash Generation and Net Debt Reconciliation (R$ millions)	3Q25 Ex-4Bio	3Q26
Adjusted EBIT	**627.8**	**723.7**
NPV adjustment	(71.1)	(59.8)
Non-recurring effects	56.2	(18.6)
Income tax (34%)	(208.4)	(219.4)
Depreciation	255.2	298.5
Impairment provision (4Bio)	-	0.2
Others	125.2	46.5
Resources from operations	**784.9**	**771.1**
Cash cycle*	123.5	(394.8)
Other assets (liabilities)**	74.4	202.1
Operating cash flow	**982.7**	**578.5**
Investments	(367.1)	(418.3)
Free cash flow	**615.6**	**160.2**
Investment activities in investees	(31.5)	(31.7)
Interest on equity and dividends	(0.1)	(0.1)
Income tax paid over interest on equity	(18.4)	(27.6)
Net financial expenses***	(145.1)	(119.9)
Tax benefit (fin. exp., IoE, dividends)	97.2	95.1
Total cash flow (ex-4Bio)	**517.7**	**75.9**
Effects from discontinued operations (4Bio)	40.6	(19.0)
Total (including 4Bio effects)	**558.3**	**56.8**

*Includes adjustments to discounted receivables. **Incl. NPV. ***Excl. NPV.

We generated R$ 56.8 million in 3Q26. This includes a cash generation in resources from operations of R$ 771.1 million (5.9% of gross revenue), and an operating cash flow of R$ 578.5 million.

We invested R$ 192.7 million in working capital and R$ 418.3 million in CAPEX, comprising of R$ 175.4 million for new pharmacy openings, R$ 90.5 million for maintenance and renovation of existing pharmacies, R$ 86.8 million for technology, R$ 61.9 million for logistics and R$ 3.8 million for other projects.

Net financial expenses totaled R$ 119.9 million in 3Q26, partially offset by a tax deduction of R$ 95.1 million related to financial expenses and interest on equity (IoE). Finally, we announced R$ 159.8 million in IoE in 3Q26.

INDEBTEDNESS

Net debt ex-4Bio (R$ millions)	3Q25	4Q25	1Q26	2Q26	3Q26
Short-term debt	522.5	508.1	425.5	365.3	417.3
Long-term debt	2,760.1	3,359.6	3,236.1	3,087.4	3,088.6
Total gross debt	**3,282.6**	**3,867.8**	**3,661.5**	**3,452.6**	**3,505.9**
(-) Cash and equivalents	339.6	358.6	441.8	536.5	504.0
Net debt	**2,943.0**	**3,509.1**	**3,219.7**	**2,916.1**	**3,001.9**
Discounted receivables	514.7	800.3	953.6	808.9	621.1
Advances to suppliers	(3.7)	-	-	(25.7)	-
Sale of 4Bio - Pending receivables	-	-	-	(716.4)	(697.4)
Investment put/call options (estimated)	22.8	15.5	15.9	16.6	17.1
Adjusted net debt	**3,476.7**	**4,324.9**	**4,189.2**	**2,999.6**	**2,942.7**
LTM adjusted EBITDA	3,056.3	3,303.1	3,500.7	3,655.0	3,786.2
Adjusted net debt/LTM EBITDA	**1.1x**	**1.3x**	**1.2x**	**0.8x**	**0.8x**


We ended the 3Q26 with an adjusted net debt of R$ 2,942.7 million, corresponding to a financial leverage ratio of 0.8x the adjusted EBITDA for the last 12 months, a 0.3x leverage reduction vs. the prior year. This reduction is comprised of 0.1x from the regular cash generation of operations and 0.2x from the sale of 4Bio.

Our adjusted net debt considers a balance of R$ 621.1 million in discounted receivables, R$ 697.4 million in pending receivables related to the sale of 4Bio and R$ 17.1 million in obligations related to put/call options for remaining equity interests in investee companies.

Gross debt totaled R$ 3,505.9 million, fully comprised by the issuance of Debentures and Real Estate Receivables Certificates (CRIs), all with a reaffirmed AAA.br rating from Moody's. Of total indebtedness, 88% is long-term and 12% is short-term. We ended the quarter with a total cash and equivalents position of R$ 504.0 million.

We highlight that, despite already recording a low leverage of 0.8x, we expect additional cash generation over time from the recovery of ICMS-ST taxes in the state of São Paulo.

TOTAL SHAREHOLDER RETURNS



Our share price increased by 10.0% in 3Q26, while the IBOVESPA index increased by 7.0%. During the period, the average daily trading volume (ADTV) was of R$ 192.2 million.

Since the IPO of Drogasil in June 2007, we achieved a cumulative share appreciation of 2,220%, compared to only 238% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 18.5%.

Considering the IPO of Raia in December 2010, the cumulative return amounted to 566%, compared to 174% for the IBOVESPA. Including shareholder distributions, this equates to an average annual return of 13.7%.

IFRS-16

Since 2019, the financial statements have been prepared in accordance with IFRS 16. However, for historical comparability purposes, the figures presented in this report exclude the effects of this standard, as we believe the previous accounting approach better reflects the economic reality of our business. On RD Saúde's Investor Relations website (ir.rdsaude.com.br), the financial statements can be found in the 'Results Spreadsheets' section.

Income Statement *(R$ millions)*	3Q26 Pre IFRS 16	3Q26 IFRS 16	Change Δ 3Q26
Gross Revenue	**13,163.3**	**13,163.3**	**0.0**
Gross Profit	**3,795.6**	**3,797.3**	**1.7**
Gross Margin	28.8%	28.8%	0.0 pp
Selling Expenses	(2,429.0)	(2,061.2)	367.7
G&A	(342.9)	(342.0)	0.9
Total Expenses	**(2,771.9)**	**(2,403.2)**	**368.6**
as % of Gross Revenue	21.1%	18.3%	(2.8 pp)
Adjusted EBITDA	**1,023.7**	**1,394.1**	**370.3**
as % of Gross Revenue	7.8%	10.6%	2.8 pp
Non-Recurring Expenses / Revenues	(18.6)	(16.5)	2.0
Depreciation and Amortization	(300.0)	(561.5)	(261.5)
Financial Results	(174.9)	(314.0)	(139.1)
Income Tax	(102.2)	(92.6)	9.6
Net income ex-4Bio	**426.9**	**408.3**	**(18.6)**
as % of Gross Revenue	3.2%	3.1%	(0.1 pp)
Net Income	**426.9**	**408.2**	**(18.6)**
as % of Gross Revenue	3.2%	3.1%	(0.1 pp)

Balance Sheet *(R$ millions)*	3Q26 Pre IFRS 16	3Q26 IFRS 16	Change Δ 3Q26
Assets	**20,766.0**	**25,624.7**	**4,858.6**
Current Assets	**14,636.7**	**14,636.7**	**(0.0)**
Non-Current Assets	**6,129.3**	**10,988.0**	**4,858.6**
Income Tax and Social Charges deferred	53.3	291.0	237.7
Other Credits	560.8	560.4	(0.5)
Investments	0.2	0.0	(0.2)
Right of use	0.0	4,621.5	4,621.5
Liabilities and Shareholder's Equity	**20,766.0**	**25,624.7**	**4,858.6**
Current Liabilities	**9,445.7**	**10,479.1**	**1,033.3**
Financial Leases	0.0	1,039.8	1,039.8
Other Accounts Payable	610.2	603.8	(6.4)
Non-Current Liabilities	**3,307.1**	**7,594.1**	**4,287.0**
Financial Leases	0.0	4,287.0	4,287.0
Shareholder's Equity	**8,013.2**	**7,551.5**	**(461.7)**
Income Reserves	2,489.1	2,075.7	(413.4)
Accrued Income	528.2	479.8	(48.3)
Equity Adjustments	63.0	63.0	(0.1)

Cash Flow *(R$ millions)*	3Q26 Pre IFRS 16	3Q26 IFRS 16	Change Δ 3Q26
Adjusted EBIT	**723.7**	**832.6**	**108.9**
Non-Recurring Effects	(18.6)	(16.5)	2.0
Income Tax (34%)	(219.4)	(257.1)	(37.7)
Depreciation	298.5	561.5	263.0
Rental Expenses	0.0	(370.7)	(370.7)
Impairment provision (4Bio)	0.2	0.2	0.0
Others	46.5	81.2	34.7
Resources from Operations	**771.1**	**771.4**	**0.2**
Operating Cash Flow	**578.5**	**578.5**	**0.0**
Investments	**(418.3)**	**(418.3)**	**0.0**
Free Cash Flow	**160.2**	**160.2**	**0.0**
Total cash flow (ex-4Bio)	**75.9**	**75.9**	**0.0**
Total cash flow (with 4Bio)	**56.8**	**56.8**	**0.0**

GLOSSARY

OTC – Over the Counter	**MSSS/SSS – Mature Same-Store Sales/Same-Store Sales**
Digital sales – Sales through digital channels, such as apps, e-commerce, phone, digital partners, among others	**LTM** – Last Twelve Months
DC – Distribution Center	**NPV** – Net Present Value
CMED – Inter-ministerial government body responsible for the economic regulation of Brazil's medicine market	**EVP** – Employee Value Proposition
EBITDA – Earnings Before Interest, Taxes, Depreciation and Amortization	**Adjusted EBITDA** – EBITDA excluding non-recurring results

RESULTS CONFERENCE CALL

November 04, 2026 - 10:00 AM (UTC-3), with simultaneous translation to English.

Access link
https://www.resultadosrdsaude.com.br/

For more information, please contact our Investor Relations department: ri@rdsaude.com.br

Consolidated adj. income statement (R$ thousands)	3Q25 Resubmitted	3Q26
Gross revenue	**11,347,942**	**13,163,282**
Taxes, deductions and returns	(767,440)	(1,754,278)
Net revenue	**10,580,502**	**11,409,004**
Cost of goods sold	(7,323,211)	(7,613,390)
Gross profit	**3,257,291**	**3,795,614**
% of gross revenue	28.7%	28.8%
Selling expenses	(2,064,781)	(2,428,957)
General and administrative expenses	(299,919)	(342,917)
Operational expenses	**(2,364,700)**	**(2,771,875)**
% of gross revenue	(20.8%)	(21.1%)
Adjusted EBITDA	**892,592**	**1,023,739**
% of gross revenue	7.9%	7.8%
Depreciation and amortization	(264,817)	(300,007)
Adjusted EBIT	**627,775**	**723,732**
Financial expenses	(340,850)	(337,366)
Financial revenue	129,924	162,494
Adjusted financial results	**(210,926)**	**(174,873)**
Equity equivalence	1,034	(1,253)
Adjusted EBT	**417,883**	**547,606**
Income tax and social charges	(71,071)	(108,468)
Adjusted net income ex-4Bio	**346,812**	**439,139**
% of gross revenue	3.1%	3.3%
Discontinued operations (4Bio)	55,174	(15)
Adjusted net income	**401,986**	**439,124**
% of gross revenue	3.5%	3.3%

Consolidated income statement (R$ thousands)	3Q25 Resubmitted	3Q26
Gross revenue	**11,347,942**	**13,163,282**
Taxes, deductions and returns	(767,440)	(1,754,278)
Net revenue	**10,580,502**	**11,409,004**
Cost of goods sold	(7,323,211)	(7,613,390)
Gross profit	**3,257,291**	**3,795,614**
Selling expenses	(2,064,781)	(2,428,957)
General and administrative expenses	(299,919)	(342,917)
Other operational expenses, net	56,244	(18,563)
Operational expenses	**(2,308,456)**	**(2,790,438)**
EBITDA	**948,835**	**1,005,176**
Depreciation and amortization	(264,817)	(300,007)
EBIT	**684,018**	**705,169**
Financial expenses	(340,850)	(337,366)
Financial revenue	129,924	162,494
Financial results	**(210,926)**	**(174,873)**
Equity equivalence	1,034	(1,253)
EBT	**474,126**	**529,043**
Income tax and social charges	(90,194)	(102,156)
Net income ex-4Bio	**383,933**	**426,887**
Results of discontinued operations (4Bio)	92,145	(15)
Net income	**476,078**	**426,872**

Assets (R$ thousands)	3Q25	3Q26
Cash and cash equivalents	339,615	503,986
Financial investments	102,050	123,210
Accounts receivable	2,848,274	3,372,755
Inventories	8,125,437	8,568,312
Taxes receivable	466,246	908,247
Anticipated expenses	115,993	170,426
Judicial deposits	6,825	3,027
Assets of investment for sale (4Bio)	1,504,998	-
Other accounts receivable	608,926	986,743
Current assets	14,118,364	14,636,706
Deposit in court	58,853	65,317
Taxes receivable	233,345	270,646
Income tax and social charges deferred	46,164	53,301
Other credits	9,951	560,844
Investments	16,660	186
Property, plant and equipment	2,822,576	3,102,481
Intangible	2,064,727	2,076,551
Non-current assets	5,252,276	6,129,326
TOTAL ASSETS	**19,370,640**	**20,766,031**

Liabilities and shareholder equity (R$ thousands)	3Q25	3Q26
Suppliers	5,739,195	6,340,844
Loans and financing	522,497	417,271
Salaries and social charges payable	895,260	1,044,588
Taxes payable	453,140	570,626
Dividends and interest on equity	338,196	437,411
Provision for lawsuits	48,336	24,810
Liabilities of investment for sale (4Bio)	551,325	-
Other accounts payable	442,815	610,196
Current liabilities	8,990,764	9,445,746
Loans and financing	2,760,116	3,088,611
Provision for lawsuits	143,283	167,493
Income tax and social charges deferred	2,356	(49)
Other accounts payable	64,948	51,024
Non-current liabilities	2,970,703	3,307,078
Common stock	4,000,000	4,750,000
Capital reserves	125,346	172,087
Revaluation reserve	10,991	10,862
Income reserves	2,529,320	2,489,084
Accrued income	666,109	528,151
Equity adjustments	62,969	63,023
Non controller interest	14,437	-
Shareholder equity	7,409,172	8,013,207
TOTAL LIABILITIES & SHAREHOLDER EQUITY	**19,370,640**	**20,766,031**

Cash Flow (R$ thousands)	3Q25	3Q26
Earnings before Income Tax and Social Charges	**566,263**	**529,043**
Adjustments		
Depreciation and Amortization	256,356	298,522
Compensation plan with restricted shares, net	(5,761)	12,265
Interest over additional stock option	8,325	569
PP&E and Intangible Assets residual value	7,717	7,556
Provisioned Lawsuits	44,727	28,375
Provisioned Inventory Loss	8,939	(1,777)
Provision for Doubtful Accounts	5,500	3,918
Provisioned Store Closures	(330)	(3,810)
Interest Expenses	155,720	124,905
Debt Issuance Costs Amortization	2,326	1,891
Equity Equivalence Result	(1,026)	1,235
Provision for realization of recoverable investment	-	206
	1,048,756	**1,002,898**
Assets and Liabilities variation		
Clients and Other Accounts Receivable	(387,034)	(280,926)
Inventories	(183,482)	(232,639)
Other Short Term Assets	18,108	(120,328)
Suppliers	465,443	(43,370)
Salaries and Social Charges	118,243	119,033
Taxes Payable	6,674	161,244
Other Liabilities	(107,088)	(34,661)
Rents Payable	5,004	(15,613)
Cash from Operations	**984,624**	**555,638**
Interest Paid	(122,531)	(73,499)
Income Tax and Social Charges Paid	(81,744)	(43,401)
Paid lawsuits	(29,694)	(23,370)
Discontinued operational activities (4Bio)	-	2,252
Net Cash from (invested) Operational Activities	**750,655**	**417,620**
Investment Activities Cash Flow		
PP&E and Intangible Acquisitions	(378,062)	(463,979)
PP&E Sale Payments	573	-
Restricted Investments	(23,772)	(6,761)
Acquisitions and capital contributions in investments, net	-	(20,700)
Cash from divestments	-	41,411
Net Cash from Investment Activities	**(401,261)**	**(450,029)**
Financing Activities Cash Flow		
Payments	(440,000)	-
Interest on Equity and Dividends Paid	(75)	(105)
Net Cash from Funding Activities	**(440,075)**	**(105)**
Cash and equivalents in the beggining of the period (with 4Bio)	**527,020**	**536,500**
Cash and equivalents net increase (with 4Bio)	(90,681)	(32,514)
Cash and equivalents in the end of the period (with 4Bio)	**436,339**	**503,986**

Balance sheets
September 30, 2026
All amounts in thousands of reais

Assets	Note	Parent Company Sept/26	Parent Company Dec/25	Consolidated Sept/26	Consolidated Dec/25
Current assets					
Cash and cash equivalents	5	270,859	296,965	503,985	509,619
Financial investments	6	28,922	28,112	123,210	19,120
Trade receivables	7	3,231,396	2,757,988	3,372,755	3,400,585
Inventories	8	8,562,936	9,127,427	8,568,312	9,576,343
Recoverable taxes	9	888,614	509,584	908,247	541,373
Other current assets	-	913,450	585,693	986,717	647,316
Prepaid expenses	-	161,561	112,816	170,426	116,027
Related parties	27	113,778	96,371	-	89,095
Judicial deposits	18	3,027	4,970	3,027	4,970
		14,174,543	**13,519,926**	**14,636,679**	**14,904,448**
Non-current assets					
Long-term receivables					
Judicial deposits	18	65,291	61,226	65,317	296,349
Recoverable taxes	9	270,646	227,331	270,646	255,077
Deferred income tax and social contribution	19.2	237,716	204,880	291,010	357,487
Prepaid expenses	-	5,224	6,824	5,224	6,824
Other non-current assets	-	554,911	156	555,190	336
		1,133,788	**500,417**	**1,187,387**	**916,073**
Investments	10	490,069	1,390,158	-	19,463
Property, plant and equipment	11	3,063,142	2,891,356	3,102,481	2,942,880
Intangible assets	12	1,750,064	1,762,278	2,076,591	2,051,563
Right-of-use assets	17	4,620,498	4,329,246	4,621,536	4,336,048
		9,923,773	**10,373,038**	**9,800,608**	**9,349,954**
		11,057,561	**10,873,455**	**10,987,995**	**10,266,027**
Total assets		**25,232,104**	**24,393,381**	**25,624,674**	**25,170,475**

Liabilities and equity	Note	Parent Company Sept/26	Parent Company Dec/25	Consolidated Sept/26	Consolidated Dec/25
Current liabilities					
Suppliers	14	6,172,827	6,425,749	6,076,834	6,680,650
Liabilities with senior quotaholders in FIDC	15	-	-	253,375	228,549
Borrowings	16	417,270	508,137	417,270	508,137
Leases payable	17	1,039,306	1,019,344	1,039,767	1,021,147
Salaries and social charges	-	983,269	737,699	1,044,587	772,590
Taxes and contributions	-	432,287	351,343	438,793	373,913
Dividends and interest on capital	-	437,411	2,566	437,411	2,566
Income tax and social contribution	-	115,462	35,632	131,834	43,262
Provision for legal claims	18	24,810	58,220	24,810	58,220
Related parties	27	22,051	22,366	-	22,366
Other current liabilities	-	464,489	428,137	614,395	482,500
		10,109,182	**9,589,193**	**10,479,076**	**10,193,900**
Non-current liabilities					
Borrowings	16	3,088,611	3,359,618	3,088,611	3,359,618
Leases payable	17	4,286,338	3,939,887	4,286,985	3,945,165
Provision for legal claims	18	167,483	135,298	167,493	248,853
Payables for acquisition of subsidiaries	-	17,147	15,518	17,147	15,518
Provisions for losses on investments	10	-	-	1,212	-
Other non-current liabilities	-	11,852	31,738	32,659	71,453
		7,571,431	**7,482,059**	**7,594,107**	**7,640,607**
Total liabilities		**17,680,613**	**17,071,252**	**18,073,183**	**17,834,507**
Equity	21				
Attributable to owners of the Company					
Share capital	-	4,750,000	4,750,000	4,750,000	4,750,000
Capital reserves	-	172,088	139,291	172,088	139,291
Revenue reserves	-	2,075,725	2,075,725	2,075,725	2,075,725
Proposed additional dividend	-	-	283,184	-	283,184
Carrying value adjustments	-	73,831	73,929	73,831	73,929
Retained earnings	-	479,847	-	479,847	-
		7,551,491	**7,322,129**	**7,551,491**	**7,322,129**
Noncontrolling interests	-	-	-	-	13,839
Total equity		**7,551,491**	**7,322,129**	**7,551,491**	**7,335,968**
Total liabilities and equity		**25,232,104**	**24,393,381**	**25,624,674**	**25,170,475**

Voltar

Statements of income

	Note	Parent Company				Consolidated			
		3rd Quarter/26	Sept/26	3rd Quarter/25	Sept/25	3rd Quarter/26	Sept/26	3rd Quarter/25 Restated	Sept/25 Restated
Net sales revenue	22	11,294,390	32,816,958	10,531,346	29,786,890	11,409,006	33,039,993	10,580,432	29,928,018
Cost of sales and services	23	(7,574,006)	(22,061,500)	(7,295,917)	(20,637,728)	(7,611,705)	(22,150,664)	(7,321,761)	(20,711,277)
Gross profit		**3,720,384**	**10,755,458**	**3,235,429**	**9,149,162**	**3,797,301**	**10,889,329**	**3,258,671**	**9,216,741**
Operating (expenses) income									
Selling	23	(2,514,688)	(7,337,955)	(2,154,159)	(6,217,471)	(2,535,774)	(7,370,835)	(2,159,649)	(6,234,777)
General and administrative	23	(387,465)	(1,113,152)	(362,964)	(1,055,972)	(428,943)	(1,192,181)	(381,188)	(1,111,269)
Other operating income/(expenses)	24	(16,502)	(202,688)	60,735	49,747	(16,521)	(202,330)	60,668	53,715
Equity in the results of subsidiaries	10	11,292	36,190	91,734	168,934	(1,237)	(1,652)	1,027	(682)
		(2,907,363)	**(8,617,605)**	**(2,364,654)**	**(7,054,762)**	**(2,982,475)**	**(8,766,998)**	**(2,479,142)**	**(7,293,013)**
Operating profit before finance results		**813,021**	**2,137,853**	**870,775**	**2,094,400**	**814,826**	**2,122,331**	**779,529**	**1,923,728**
Finance income (costs)									
Finance income	25	155,497	438,869	119,313	299,685	162,493	450,759	129,924	322,499
Finance costs	25	(476,236)	(1,413,761)	(456,975)	(1,250,996)	(476,496)	(1,415,130)	(457,093)	(1,251,518)
		(320,739)	**(974,892)**	**(337,662)**	**(951,311)**	**(314,003)**	**(964,371)**	**(327,169)**	**(929,019)**
Profit before income tax and social contribution		**492,282**	**1,162,961**	**533,113**	**1,143,089**	**500,823**	**1,157,960**	**452,360**	**994,709**
Income tax and social contribution									
Current	-	(117,067)	(203,995)	(109,615)	(213,994)	(127,890)	(219,553)	(111,410)	(219,715)
Deferred	-	33,047	32,791	30,474	62,848	35,329	33,389	28,523	60,993
	19	(84,020)	(171,204)	(79,141)	(151,146)	(92,561)	(186,164)	(82,887)	(158,722)
Profit before discontinued operations		**408,262**	**991,757**	**453,972**	**991,943**	**408,262**	**971,796**	**369,473**	**835,987**
Profit from discontinued operations		**(15)**	**(15)**	**-**	**-**	**(15)**	**19,946**	**92,208**	**173,716**
Profit for the period		**408,247**	**991,742**	**453,972**	**991,943**	**408,247**	**991,742**	**461,681**	**1,009,703**
Attributable to:									
Owners of the Company	-	408,247	991,742	453,972	991,943	408,247	991,742	453,972	991,943
Noncontrolling interests	-	-	-	-	-	-	-	7,709	17,760
		408,247	**991,742**	**453,972**	**991,943**	**408,247**	**991,742**	**461,681**	**1,009,703**
Net basic earnings per share	20	0.24776	0.60188	0.27565	0.60230	0.24776	0.60188	0.27565	0.60230
Net diluted earnings per share	20	0.24445	0.59384	0.27338	0.59734	0.24445	0.59384	0.27338	0.59734

Statements of comprehensive income

	Note	Parent Company				Consolidated			
		3rd Quarter/26	Sept/26	3rd Quarter/25	Sept/25	3rd Quarter/26	Sept/26	3rd Quarter/25	Sept/25
Profit for the period		**408,247**	**991,742**	**453,972**	**991,943**	**408,247**	**991,742**	**461,681**	**1,009,703**
Components of comprehensive income	-	-	-	-	-	-	-	-	-
Other comprehensive income that will affect the result in a subsequent period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period		**408,247**	**991,742**	**453,972**	**991,943**	**408,247**	**991,742**	**461,681**	**1,009,703**
Attributable to:									
Owners of the Company	-	408,247	991,742	453,972	991,943	408,247	991,742	453,972	991,943
Noncontrolling interests	-	-	-	-	-	-	-	7,709	17,760
Total		**408,247**	**991,742**	**453,972**	**991,943**	**408,247**	**991,742**	**461,681**	**1,009,703**

Statements of changes in equity
Nine-month period ended September 30, 2026
All amounts in thousands of reais

	Attributable to owners of the Company															
		Capital reserves				Revenue reserves					Carrying value adjustments					
	Share capital	Special monetary adjustment	Goodwill on issue / sale of shares	Treasury shares	Restricted shares and other	Legal	Statutory	Tax incentives	Retained earnings	Proposed additional dividend	Revaluation reserve	Transactions with noncontrolling interests	Other comprehensive income	Total	Noncontrolling interests	Total equity
At December 31, 2024	**4,000,000**	**10,191**	**135,872**	**(124,991)**	**90,237**	**378,498**	**983,106**	**816,597**	**-**	**69,895**	**11,087**	**3,262**	**59,706**	**6,433,460**	**13,427**	**6,446,887**
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	95	-	(95)	-	-	-	-	-
Interest on capital expired	-	-	-	-	-	-	-	-	399	-	-	-	-	**399**	-	**399**
Interest on capital for 2024 approved at the AGEM of April 22, 2025	-	-	-	-	-	-	-	-	-	(69,895)	-	-	-	**(69,895)**	-	**(69,895)**
Restricted share plan - vesting period	-	-	-	-	13,936	-	-	-	15,800	-	-	-	-	**29,736**	-	**29,736**
Restricted share plan - delivery	-	-	7,606	19,810	(27,896)	-	-	-	-	-	-	-	-	**(480)**	-	**(480)**
Restricted shares – delivery of restricted shares	-	-	-	1,100	(519)	-	-	-	-	-	-	-	-	**581**	-	**581**
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	(16,954)	**(16,954)**
Profit for the period	-	-	-	-	-	-	-	-	991,943	-	-	-	-	**991,943**	17,760	**1,009,703**
Interest on capital proposed	-	-	-	-	-	-	-	-	(390,600)	-	-	-	-	**(390,600)**	-	**(390,600)**
At September 30, 2025	**4,000,000**	**10,191**	**143,478**	**(104,081)**	**75,758**	**378,498**	**983,106**	**816,597**	**617,637**	**-**	**10,992**	**3,262**	**59,706**	**6,995,144**	**14,233**	**7,009,377**
Capital Increase approved at the Board of Directors' Meeting on December 22, 2025	750,000	-	-	-	-	-	(750,000)	-	-	-	-	-	-	**-**	-	**-**
Interest on capital expired	-	-	-	-	-	-	-	-	339	-	-	-	-	**339**	-	**339**
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	31	-	(31)	-	-	**-**	-	**-**
Restricted share plan - vesting period	-	-	-	-	13,944	-	-	-	(1)	-	-	-	-	**13,943**	-	**13,943**
Restricted share plan - delivery	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	-	**-**
Restricted shares – delivery of restricted shares	-	-	-	(1)	2	-	-	-	-	-	-	-	-	**1**	-	**1**
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	13,984	**13,984**
Profit for the period	-	-	-	-	-	-	-	-	304,918	-	-	-	-	**304,918**	(14,378)	**290,540**
Interest on capital proposed	-	-	-	-	-	-	-	-	(145,400)	536,000	-	-	-	**390,600**	-	**390,600**
Legal reserve	-	-	-	-	-	64,842	-	-	(64,842)	-	-	-	-	**-**	-	**-**
Proposed dividends - R$ 0.075890 per share (Note 21)	-	-	-	-	-	-	-	-	(130,000)	130,000	-	-	-	**-**	-	**-**
Statutory reserve	-	-	-	-	-	-	582,682	-	(582,682)	-	-	-	-	**-**	-	**-**
Withholding tax on IOC (Note 21)	-	-	-	-	-	-	-	-	-	(74,780)	-	-	-	**(74,780)**	-	**(74,780)**
Reclassification of minimum mandatory dividends to current liabilities	-	-	-	-	-	-	-	-	-	(308,036)	-	-	-	**(308,036)**	-	**(308,036)**
At December 31, 2025	**4,750,000**	**10,191**	**143,478**	**(104,082)**	**89,704**	**443,340**	**815,788**	**816,597**	**-**	**283,184**	**10,961**	**3,262**	**59,706**	**7,322,129**	**13,839**	**7,335,968**
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	98	-	(98)	-	-	**-**	-	**-**
Interest on capital expired	-	-	-	-	-	-	-	-	307	-	-	-	-	**307**	-	**307**
Restricted share plan - vesting period	-	-	-	-	29,159	-	-	-	-	-	-	-	-	**29,159**	-	**29,159**
Restricted share plan - delivery	-	-	4,739	24,316	(30,442)	-	-	-	-	-	-	-	-	**(1,387)**	-	**(1,387)**
Restricted shares – delivery of restricted shares	-	-	-	1,387	3,638	-	-	-	-	-	-	-	-	**5,025**	-	**5,025**
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	-	**-**	(13,839)	**(13,839)**
Profit for the period	-	-	-	-	-	-	-	-	991,742	-	-	-	-	**991,742**	-	**991,742**
Interest on capital proposed	-	-	-	-	-	-	-	-	(464,700)	-	-	-	-	**(464,700)**	-	**(464,700)**
Dividends for the period	-	-	-	-	-	-	-	-	(47,600)	-	-	-	-	**(47,600)**	-	**(47,600)**
Reclassification of minimum mandatory dividends to current liabilities	-	-	-	-	-	-	-	-	-	(283,184)	-	-	-	**(283,184)**	-	**(283,184)**
At September 30, 2026	**4,750,000**	**10,191**	**148,217**	**(78,379)**	**92,059**	**443,340**	**815,788**	**816,597**	**479,847**	**-**	**10,863**	**3,262**	**59,706**	**7,551,491**	**-**	**7,551,491**

Voltar

	Note	Parent Company		Consolidated	
		Sept/26	Sept/25	Sept/26	Sept/25 Restated
Cash flows from operating activities					
Profit before income tax and social contribution	-	**1,162,961**	**1,143,089**	**1,157,960**	**994,709**
Adjustments					
Depreciation and amortization	23	1,645,531	1,502,861	1,667,020	1,516,932
Compensation plan with restricted shares, net	-	32,797	14,037	32,797	14,037
Interest on additional stock option	-	1,629	9,197	1,629	9,197
Profit on sale/write-off of fixed assets and intangible assets	-	8,761	12,626	62,544	13,059
Provision for (reversal of) legal claims	18	75,558	70,420	75,568	56,905
(Reversal of) provision for inventory losses	8	(11,653)	2,232	(11,653)	2,232
(Reversal of) provision for impairment of trade receivables	7	9,766	7,190	9,597	12,908
(Reversal of) provision for pharmacies closure	11 and 12	535	(3,248)	535	(3,248)
Expenses net of interest on borrowings	16	386,048	375,850	386,048	383,787
Amortization of transaction costs of debentures	16	6,024	7,154	6,024	7,154
Equity in the results of subsidiaries	10	(36,190)	(168,934)	1,652	682
Interest expenses – leases	17	415,950	355,905	416,307	356,353
Discontinued operation		-	-	-	150,149
Gain on business combination		(19,568)	-	(19,568)	-
Provision for impairment of investment	30	203,002	-	203,002	-
		3,881,151	**3,328,379**	**3,989,462**	**3,514,856**
Changes in assets and liabilities					
Trade and other receivables	-	(483,174)	(874,235)	(638,698)	(754,380)
Inventories	-	576,144	(149,062)	603,786	(92,310)
Other assets	-	(321,126)	(125,890)	(615,710)	(239,016)
Suppliers	-	(256,015)	375,989	(48,576)	310,010
Salaries and social charges	-	245,570	219,258	289,546	225,138
Taxes and contributions	-	(261,571)	129,278	(322,724)	72,074
Other obligations	-	(210,859)	(259,307)	(319,983)	(203,077)
Rentals payable	-	9,704	10,937	9,705	11,009
Other					
Interest paid	16	(354,228)	(311,739)	(354,228)	(320,389)
Income tax and social contribution paid	-	(73,755)	(107,909)	(73,755)	(107,909)
Interest paid – leases	17	(415,950)	(355,905)	(416,307)	(356,353)
Legal claims – paid	18	(76,783)	(47,311)	(76,783)	(47,311)
Net cash provided by operating activities		**2,259,108**	**1,832,483**	**2,025,735**	**2,012,342**
Cash flows from investing activities					
Acquisition and capital contribution in investees	-	(40,970)	(107,970)	(23,000)	-
Cash acquired in business combination	10.1	-	-	144,517	-
Purchases of fixed assets and intangible assets	11 and 12	(996,395)	(950,196)	(1,048,212)	(972,000)
Proceeds from sale of fixed assets		533	573	533	573
Financial investments		-	-	(104,090)	(86,344)
Proceeds from disposal of investee		141,411	-	141,411	-
Net cash used in investing activities		**(895,421)**	**(1,057,593)**	**(888,841)**	**(1,057,771)**
Cash flows from financing activities					
Borrowings taken	16	-	500,000	-	590,000
Repayment of borrowings	16	(400,000)	(475,000)	(400,000)	(653,869)
Leases paid	-	(742,896)	(672,414)	(736,590)	(673,926)
Interest on capital and dividends paid	-	(246,897)	(308,438)	(247)	(308,438)
Redemptions – Senior quotaholders FIDC		-	-	(5,691)	-
Net cash used in financing activities		**(1,389,793)**	**(955,852)**	**(1,142,528)**	**(1,046,233)**
Increase (decrease) in cash and cash equivalents		(26,106)	(180,962)	(5,634)	(91,662)
Cash and cash equivalents at January 1	5	**296,965**	460,292	**509,619**	**528,002**
Cash and cash equivalents at September 30	5	**270,859**	**279,330**	**503,985**	**436,340**

The accompanying notes are an integral part of this interim financial information.

Statements of value added
Nine-month period ended September 30, 2026
All amounts in thousands of reais

	Parent Company				Consolidated			
	3rd Quarter/26	Sept/26	3rd Quarter/25	Sept/25	3rd Quarter/26	Sept/26	3rd Quarter/25 Restated	Sept/25 Restated
Revenue	**12,834,031**	**37,085,768**	**11,120,804**	**31,441,199**	**12,959,329**	**37,326,196**	**11,172,343**	**31,585,177**
Gross sales and services	12,832,049	37,078,186	11,122,409	31,484,944	12,957,347	37,318,598	11,173,948	31,628,922
Other income	5,490	11,871	3,172	9,702	5,490	11,887	3,172	9,702
Provision for (reversal of) impairment of trade receivables	(3,508)	(4,289)	(4,777)	(53,447)	(3,508)	(4,289)	(4,777)	(53,447)
Inputs acquired from third parties	**(8,452,292)**	**(25,099,869)**	**(7,453,700)**	(21,031,753)	**(8,500,399)**	**(25,200,204)**	**(7,480,741)**	**(21,112,057)**
Cost of sales and services	(7,568,452)	(22,354,313)	(6,733,321)	(18,989,600)	(7,604,475)	(22,438,346)	(6,757,210)	(19,057,252)
Materials, energy, outsourced services and other	(882,559)	(2,541,479)	(720,379)	(2,042,153)	(894,643)	(2,557,781)	(723,531)	(2,054,805)
(Loss) and recovery of asset values (Note 30)	(1,281)	(204,077)	-	-	(1,281)	(204,077)	-	-
Gross value added	**4,381,739**	**11,985,899**	**3,667,104**	**10,409,446**	**4,458,930**	**12,125,992**	**3,691,602**	**10,473,120**
Depreciation and amortization	(546,820)	(1,596,525)	(503,323)	(1,469,260)	(561,479)	(1,618,763)	(506,704)	(1,477,999)
Net value added generated by the entity	**3,834,919**	**10,389,374**	**3,163,781**	**8,940,186**	**3,897,451**	**10,507,229**	**3,184,898**	**8,995,121**
Value added received through transfer	**175,014**	**498,666**	**216,644**	**485,375**	**168,756**	**470,898**	**135,728**	**342,269**
Equity in the results of subsidiaries	11,292	36,190	91,734	168,934	(1,237)	(1,652)	1,027	(682)
Finance income	156,722	441,953	119,810	300,638	162,993	452,027	129,601	327,147
Other	7,000	20,523	5,100	15,803	7,000	20,523	5,100	15,804
Total value added to distribute - Continuing operations	**4,009,933**	**10,888,040**	3,380,425	9,425,561	**4,066,207**	**10,978,127**	**3,320,626**	**9,337,390**
Total value added to distribute - Discontinued operations	-	-	-	-	-	177,773	196,836	472,681
Total value added to distribute	**4,009,933**	**10,888,040**	**3,380,425**	**9,425,561**	**4,066,207**	**11,155,900**	**3,517,462**	**9,810,071**
Total distribution of value added	**4,009,933**	**10,888,040**	**3,380,425**	**9,425,561**	**4,066,207**	**11,155,900**	**3,517,462**	**9,810,071**
Total distribution of value added – Discontinued operations	-	-	-	-	-	177,773	196,836	472,681
Value added distributed and retained – Continuing operations	**4,009,933**	**10,888,040**	**3,380,425**	**9,425,561**	**4,066,207**	**10,978,127**	**3,320,740**	**9,337,559**
Personnel	**1,217,501**	**3,560,565**	1,039,788	3,051,257	**1,245,241**	**3,612,868**	**1,051,567**	**3,084,758**
Direct remuneration	963,524	2,771,691	**809,883**	**2,396,313**	987,611	2,814,179	819,023	2,422,376
Benefits	179,823	556,619	162,150	452,192	182,643	564,193	164,196	457,896
Unemployment compensation fund	74,154	232,255	67,755	202,752	74,987	234,496	68,348	204,486
Taxes and contributions	**1,827,953**	**4,691,479**	1,372,061	3,921,310	**1,856,157**	**4,747,751**	**1,384,761**	**3,954,711**
Federal	498,753	1,115,129	**295,037**	**818,867**	522,913	1,159,983	305,599	846,216
State	1,315,455	3,530,089	1,063,252	3,061,186	1,317,212	3,534,878	1,063,617	3,062,053
Municipal	13,745	46,261	13,772	41,257	16,032	52,890	15,545	46,442
Providers of capital	**556,232**	**1,644,254**	514,604	1,461,051	**556,547**	**1,645,712**	**514,825**	**1,461,934**
Interest	475,916	1,412,665	**439,054**	**1,232,267**	475,981	1,413,505	439,077	1,232,479
Rentals	80,316	231,589	75,550	228,784	80,566	232,207	75,748	229,455
Interest on capital and dividends	**408,247**	**991,742**	453,972	991,943	**408,262**	**971,796**	**369,473**	**835,987**
Interest on capital	159,800	464,700	**140,700**	**390,600**	159,800	464,700	140,700	390,600
Retained earnings for the period	248,447	527,042	313,272	601,343	248,462	507,096	221,064	427,627
Noncontrolling interests in retained earnings	-	-	-	-	-	-	7,709	17,760

The accompanying notes are an integral part of this interim financial information.

1. Operations

Raia Drogasil S.A. ("Company" or "RD Saúde" or "Parent Company") is a publicly-held company with its headquarters at Av. Corifeu de Azevedo Marques, 3.097, São Paulo – SP, listed on the Novo Mercado ("New Market" listing segment of B3 S.A. - Brasil, Bolsa, Balcão, under ticker RADL3. RD Saúde was created in November 2011 from the merger between Droga Raia and Drogasil chains that, together, combine more than 200 years of history. Droga Raia was founded in 1905 and Drogasil in 1935 and today form the leading chain, both in number of pharmacies and in revenues.

On March 18, 2024, the Company changed its brand to "RD Saúde", reflecting its goal to lead health promotion in Brazil. In addition to the pharmaceutical retail segment, RD Saúde focuses on comprehensive health, seeking the well-being of the community and offering high-quality services and products.

RD Saúde and its subsidiaries (together "Group" or "Consolidated") are mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. The Group conducts its sales through 3,770 pharmacies (3,547 pharmacies – Dec/25), present in all 26 Brazilian states and the Federal District (26 states and the Federal District – Dec/25), as presented below:

	Consolidated	
State	**Sept/26**	**Dec/25**
Southeast region	**2,131**	**2,004**
São Paulo	1,485	1,415
Rio de Janeiro	295	263
Minas Gerais	269	249
Espírito Santo	82	77
Northeast region	**579**	**542**
Bahia	147	126
Pernambuco	122	117
Ceará	116	108
Maranhão	45	44
Sergipe	32	34
Rio Grande do Norte	34	33
Paraíba	31	30
Alagoas	28	26
Piauí	24	24
South region	**478**	**450**
Paraná	217	201
Rio Grande do Sul	140	137
Santa Catarina	121	112
Midwest region	**423**	**396**
Goiás	163	155
Federal District	129	117
Mato Grosso do Sul	70	68
Mato Grosso	61	56
North region	**159**	**155**
Pará	63	59
Amazonas	31	30
Tocantins	29	29
Rondônia	20	20
Acre	6	7
Amapá	5	5
Roraima	5	5
Total	**3,770**	**3,547**

During the current period, 236 pharmacies were opened and 13 pharmacies were closed (until the third quarter of 2025, 233 pharmacies were opened and 10 were closed). All pharmacies closures were carried out to optimize our pharmacies portfolio, with positive expectations of return. RD Saúde's pharmacies, as well as the Group's e-commerce demands, are supplied by sixteen distribution centers located in thirteen states: São Paulo, Rio de Janeiro, Minas Gerais, Espirito Santo, Paraná, Goiás, Pernambuco, Bahia, Ceará, Rio Grande do Sul, Mato Grosso, Amazonas and Pará.

RD Ventures Fundo de Investimento em Participações – Multiestratégia ("FIP RD Ventures") is an exclusive fund created as a platform that seeks to invest in businesses that contribute to the Company's growth strategy and accelerate the journey of digitalization in health.

Dr. Cuco Desenvolvimento de Software Ltda. ("Dr. Cuco") is a digital care platform focused on adherence to treatment.

Impulso Soluções de Mídia Ltda. ("Impulso") is RD's Retail Media solution, a platform that offers a high reach potential through personalized audiences with retail data and high accuracy of results. This allows advertisers to analyze the performance of online and offline campaigns and to be present at all times of the consumer journey.

SafePill Comércio Varejista de Medicamentos Manipulados Ltda. ("Dose Certa + Cuidado") is focused on adherence to treatments and offers services for Management of Self-Care Home Treatments.

ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil") is the first startup of the Brazilian compounding pharmacies market, operating as a marketplace platform that provides customers with immediate online access to compounding pharmacies.

Kymberg Farmacêutica do Brasil Ltda. ("Kymberg") is a pharmaceutical company specialized in the production of medicines.

RD Saúde holds all the subordinated quotas of RD Fundo de Investimento em Direitos Creditórios Crédito Corporativo ("RD FIDC"). The Company consolidates RD FIDC's financial information because it believes that a significant portion of the risks and rewards related to profitability is linked to the subordinated quotas held by RD Saúde.

Hereinafter, the entities mentioned above will be collectively referred to as "Subsidiaries".

1.1. Sale of subsidiary 4Bio

On March 3, 2026, the Company entered into a Share Purchase and Sale Agreement and Other Covenants for the sale of its entire equity interest in its subsidiary 4Bio Medicamentos S.A. "4Bio" to Health Ventures S.A., a direct subsidiary of Profarma Distribuidora de Produtos Farmacêuticos S.A.

The base value of the transaction is R$ 600 million, including the maintenance, at 4Bio, as of the closing date of the transaction, of net cash of R$ 80 million, in addition to other customary adjustments to working capital and net debt, typical of transactions of this nature. The amount will be paid in six (6) installments, as follows: (i) R$ 100 million on the closing date of the transaction; and (ii) five (5) annual installments of R$ 100 million, adjusted by the CDI.

In addition, the contract provides for the right to recognition of an estimated gain from assets of R$ 127 million, related to the ICMS tax rate differential (DIFAL), for which a favorable ruling has already been issued by the Federal Supreme Court (STF), including a final and unappealable decision for an amount equivalent to R$ 12 million. The funds will be released upon the withdrawal of the judicial deposits, once the decision becomes final.

The sale was completed on May 4, 2026, as described in Note 31.

Further details regarding this transaction, as well as the results of discontinued operations for the periods ended September 30, 2026 and 2025, are provided in Note 30.

2. Presentation of quarterly information

In conformity with NBC TG 24(R2), authorization to issue these financial statements was granted by the Company's Board of Directors on November 3, 2026.

The individual and consolidated interim financial information for the period ended September 30, 2026, included in the Quarterly Information Form (ITR), was prepared in accordance with Technical Pronouncement CPC 21(R1) – Interim Financial Reporting, issued by the Brazilian Accounting Pronouncements Committee (CPC), and in conformity with International Accounting Standard IAS 34 – Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and discloses all (and only) the applicable significant information related to the financial statements, which is consistent with the information utilized by management in the performance of its duties. The Group adopted all standards, revised standards and interpretations issued by the IFRS and CPC that were effective as of January 1, 2026.

The statement of income, statement of value added, statement of cash flows, and notes to the interim financial information for the nine-month period ended September 30, 2025 are being restated due to the sale of the subsidiary 4Bio (Note 1.1), considering the effects of such transactions in accordance with Technical Pronouncement CPC 31 / IFRS 5 – Non-current Assets Held for Sale and Discontinued Operations.

The statements of cash flows include continuing and discontinued operations in accordance with Technical Pronouncement CPC 31/IFRS 5.

The individual interim financial information is disclosed together with the consolidated interim financial information, which includes the interim financial information of the Company and its subsidiaries 4Bio, Dr. Cuco, Manipulação Raia Drogasil, Dose Certa + Cuidado, Impulso, Kymberg, FIP RD Ventures, RD FIDC and RD Log, and have been prepared in accordance with consolidation practices and applicable legal provisions.

The accounting practices adopted by the Subsidiaries were applied uniformly and consistently with those adopted by the Company. Where applicable, all transactions, balances, income and expenses between the Subsidiary and the Company are fully eliminated in the consolidated interim financial information.

This interim financial information was prepared on the historical cost basis, except for: (i) certain financial instruments; and (ii) assets and liabilities arising from business combinations measured at their fair values, when applicable. Historical cost is generally based on the fair value of the consideration paid for goods or services.

The interim financial information includes accounting estimates and requires management to exercise its judgment in the process of applying the Company's accounting policies regarding provision for inventory losses, provision for expected credit losses, appreciation of financial instruments, realization periods of recoverable taxes, the amortization and depreciation periods for fixed and intangible assets, estimate of impairment of intangible assets with indefinite useful life, provision for legal claims, fair value measurement of financial liabilities, determination of provision for taxes, recognition of revenues from commercial agreements, among others. The significant estimates and judgments are disclosed in Note 4(f).

The presentation of the individual and consolidated statements of value added is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies, while it is not required by IFRS. Therefore, under the IFRS, the presentation of such statements is considered supplementary information, and not part of the set of the interim financial information.
The interim financial information is presented in thousands of Brazilian reais (R$), which is the Group's functional and presentation currency.

3. New accounting procedures, amendments to and interpretations of standards

Standards issued but not yet effective

The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company's interim financial information are disclosed below. The Company intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.

CBPS 1 / IFRS S1 - General Requirements for Disclosure of Sustainability-related Financial Information; CBPS 2 / IFRS S2 - Climate-related Disclosures	CBPS 1 / IFRS S1 - General Requirements for Disclosure of Sustainability-related Financial Information; This standard is to require an entity to disclose information about its sustainability-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. The Company is assessing the impact of this standard for early adoption or compliance with the term defined therein. CBPS 2 / IFRS S2 - Climate-related Disclosures The objective of this standard is to establish the requirements to identify, measure and disclose information about climate-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. Both pronouncements apply to fiscal years beginning on or after January 1, 2026, with voluntary early adoption as from January 1, 2025. The Company is assessing the possible impacts from this implementation on the presentation and disclosure of the interim financial information and has not implemented it early.
IFRS 18 - Presentation and Disclosure in Financial Statements	IFRS 18 - Presentation and Disclosure in Financial Statements replaces IAS 1 – Presentation of Financial Statements in the preparation of financial statements beginning or after January 1, 2027. IFRS 18 (i) introduces new requirements for the presentation of the statement of income, with the inclusion of three new categories of income and expenses - operating, investments and financing - two mandatory subtotals, and changes in the grouping of balances; (ii) requires the disclosure in the explanatory notes of the performance measures defined by Management; and (iii) includes changes in the statement of cash flows and new requirements for the presentation of expenses by nature or function. The Company is assessing the possible impacts from this standard on the presentation and disclosure of the interim financial information.
IFRS 19: Subsidiaries without Public Accountability: Disclosures	In May 2024, the IASB issued IFRS 19, which allows eligible entities to opt to apply reduced disclosure requirements while still applying the recognition, measurement and presentation requirements in other IFRS accounting standards. To be eligible, at the end of the reporting period, an entity must be a subsidiary as defined in IFRS 10 (CPC - 36 (R3) - Consolidated Financial Statements), cannot have public accountability and must have a parent (ultimate or intermediate) that prepares interim financial information, available for public use, that complies with the IFRS Accounting Standards. IFRS 19 will be effective for reporting periods beginning on or after January 1, 2027. The Company is assessing the possible impacts from this standard on the presentation and disclosure of the interim financial information.

Additionally, other accounting standards, amendments and interpretations have been issued recently, however they are not yet effective or did not have a material impact on this interim financial information. For the period ended September 30, 2026, the Company did not early adopt any standard and did not identify a significant impact on the interim financial information.

4. Material accounting practices

The accounting practices adopted in the preparation of this interim financial information were consistently applied in the current period and are consistent with those disclosed in Note 4 and, when related to significant accounting balances, are detailed in the notes to the financial statements for the year ended December 31, 2025, disclosed on March 3, 2026.

5. Cash and cash equivalents

	Parent Company		Consolidated	
Cash and cash equivalents items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Cash and banks	153,996	209,843	184,789	222,229
Repurchase agreements (i)	76,053	-	76,403	55,637
Automatic investments(ii)	40,810	87,122	42,793	104,596
Bank Deposit Certificates - CDB(iii)	-	-	200,000	127,157
Total	**270,859**	**296,965**	**503,985**	**509,619**

(i) Fixed-income investment with income linked to the variation of the Interbank Deposit Certificate - CDI, with immediate liquidity and without loss of income.
(ii) Short-term fixed income fund with short-term investments and automatic redemptions.
(iii) Investments in bank deposit certificate have daily liquidity and grace period of 30 days.

6. Financial investments

	Parent Company		Consolidated	
Cash and cash equivalents items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
RD Fundo de Investimento em Direitos Creditórios Corporativos	28,922	28,112	-	-
Investment fund	-	-	123,210	19,120
Total	**28,922**	**28,112**	**123,210**	**19,120**

RD Fundo de Investimento em Direitos Creditórios Corporativos ("RD FIDC")

The balance of R$ 28,922 in the Parent Company at September 30, 2026 refers to the investment in RD Fundo de Investimento em Direitos Creditórios Corporativos ("RD FIDC").

RD FIDC began its activities on February 16, 2023, established as a special fund, as provided for by CMN Resolution 2,907, of November 29, 2001, and by CVM Instruction 175/22, of December 23, 2022. On March 28, 2023, the Company made the first contribution to RD FIDC.

RD FIDC's capital structure at September 30, 2026 comprised 169,103 senior quotas held by third parties in the amount of R$ 253,375, representing 89.75% of the fund's equity, and 26,163 subordinated quotas held by RD in the amount of R$ 28,922, representing 10.25% of the fund's equity.

The purpose of RD FIDC is to provide to its quotaholders the valuation of their quotas through the investment of their funds exclusively in credit rights arising from payment transactions carried out by the Company, with the use of payment instruments for the acquisition of goods and services. The earnings of the senior quotas are paid monthly and are subject to a minimum remuneration of CDI plus 1.66% p.a.

Subordinated quotas were attributed to the Company and were recorded in current assets as interest in the securitization fund, with a balance of R$ 28,922 (R$ 28,112 – Dec/25). The subordinated quotas represent the Company's maximum exposure to the credit risks of the structure; RD Saúde has no additional liability to the senior shareholders, nor is it required to make up for the Fund's losses.

Obligations related to senior quotas constitute liabilities solely of the Fund itself, and not of RD Saúde. The FIDC, as provided for in CVM Resolution 175, operates with segregated assets and asset autonomy (CVM 175 – Art. 4; §2 of Art. 5), and its obligations are strictly limited to its net assets.

Investment Fund

Balance held by FIP RD Ventures and by RD FIDC in short-term investment funds which aim to provide to its quotaholders the valuation of their quotas through the investment of their funds in a portfolio fully comprised of federal government securities. The investment has no grace period for redemption and convertibility of the quotas, the amount may be readily invested or redeemed and the financial settlement occurs on the same day.

7. Trade receivables

	Parent Company		Consolidated	
Trade receivables items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Trade receivables	3,273,256	2,799,770	3,414,637	3,462,493
(-) Expected credit losses	(3,141)	(1,745)	(3,163)	(11,900)
(-) Adjustment to present value	(38,719)	(40,037)	(38,719)	(50,008)
Total	**3,231,396**	**2,757,988**	**3,372,755**	**3,400,585**

The detailed aging of trade receivables is presented below:

	Parent Company		Consolidated	
Maturities	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Not yet due	3,265,447	2,794,649	3,404,342	3,409,849
Overdue:				
Between 1 and 30 days	4,493	1,470	6,767	21,301
Between 31 and 60 days	1,605	1,515	1,763	6,600
Between 61 and 90 days	781	1,313	781	5,306
Between 91 and 180 days	930	823	930	6,322
Between 181 and 360 days	-	-	54	13,115
(-) Expected credit losses	(3,141)	(1,745)	(3,163)	(11,900)
(-) Adjustment to present value	(38,719)	(40,037)	(38,719)	(50,008)
Total	**3,231,396**	**2,757,988**	**3,372,755**	**3,400,585**

Days sales outstanding, represented by credit and debit cards and partnerships with companies and the Government, are approximately 45 days (45 days – Dec/2025), term that is considered part of the normal conditions inherent in the Group's operations. A substantial portion of the amounts overdue for more than 31 days is represented by collection through special plans, Medicine Benefit Program (PBM), and Popular Pharmacy Program.

The changes in expected credit losses are presented below:

Changes in expected losses	Parent Company	Consolidated
At January 1, 2025	**(978)**	**(19,169)**
Additions	(24,213)	(42,989)
Reversals	17,023	30,081
Losses	6,616	17,520
At September 30, 2025	**(1,552)**	**(14,557)**
Additions	(3,648)	(8,933)
Reversals	1,509	1,444
Losses	1,946	10,146
At December 31, 2025	**(1,745)**	**(11,900)**
Write-off due to the sale of subsidiaries	-	9,964
Additions	(14,565)	(14,565)
Reversals	4,799	4,968
Losses	8,370	8,370
At September 30, 2026	**(3,141)**	**(3,163)**

Trade receivables are classified as financial assets at amortized cost and are therefore measured as described in Note 26.1 – Impairment to the interim financial information for the period ended September 30, 2026.

8. Inventories

	Parent Company		Consolidated	
Inventory items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Goods for resale	8,687,295	9,301,674	8,692,302	9,748,264
Consumables	1,801	2,579	2,170	2,840
(-) Adjustment to present value	(62,449)	(101,462)	(62,449)	(99,397)
(-) Provision for inventory losses	(63,711)	(75,364)	(63,711)	(75,364)
Total inventories	**8,562,936**	**9,127,427**	**8,568,312**	**9,576,343**

Changes in the provision for expected losses on goods are as follows:

Changes in expected losses on goods	Parent Company/ Consolidated
At January 1, 2025	**(83,413)**
Additions	(33,859)
Write-offs	31,627
At September 30, 2025	**(85,645)**
Additions	(7,197)
Write-offs	17,478
At December 31, 2025	**(75,364)**
Additions	(13,455)
Write-offs	25,108
At September 30, 2026	**(63,711)**

For the nine-month period ended September 30, 2026, cost of goods sold recognized in the statement of income was R$ 22,067,731 (R$ 20,640,769- Sept/2025) for the Parent Company and R$ 22,086,721 (R$ 20,657,751- Sept/2025) for the Consolidated accounts (Note 23), including the amount of the write-offs of goods inventories recognized as losses for the period amounting to R$ 346,502 (R$ 353,198 - Sept/2025) for the Parent Company and R$ 346,502 (R$ 353,198 - Sept/2025) for the Consolidated.

The effect of the recognition, reversal or write-off of the provision for inventory losses is included in cost of sales in the statement of income.

9. Recoverable taxes

	Parent Company		Consolidated	
Recoverable taxes items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Taxes on profit recoverable				
Withholding Income Tax (IRRF)	2,161	3,798	13,387	7,203
Corporate Income Tax (IRPJ)	34,566	36,215	39,677	43,228
Social Contribution on Net Profit (CSLL)	14,993	14,942	18,051	17,070
Subtotal	**51,720**	**54,955**	**71,115**	**67,501**
Other recoverable taxes				
Value Added Tax on Sales and Services (ICMS) – credit balance [(i)]	258,313	183,841	258,311	198,961
ICMS – Refund of ICMS withheld in advance [(i)]	595,679	245,879	595,679	274,626
ICMS on acquisitions of property, plant and equipment items	143,753	137,962	143,753	137,962
Service Tax (ISS)	589	610	597	612
Social Integration Program (PIS)	21,607	20,746	21,626	21,286
Social Contribution on Revenue (COFINS)	87,599	92,922	87,684	95,298
National Institute of Social Security (INSS)	-	-	128	204
Subtotal	**1,107,540**	**681,960**	**1,107,778**	**728,949**
Total	**1,159,260**	**736,915**	**1,178,893**	**796,450**
Current assets	888,614	509,584	908,247	541,373
Non-current assets	270,646	227,331	270,646	255,077

(i) The ICMS credits amounting to R$ 258,313 and R$ 595,679 (R$ 183,841 and R$ 245,879 - Dec/25) for the Parent Company and R$ 258,311 and R$ 595,679 (R$ 198,961 and R$ 274,626 - Dec/25) for the Consolidated accounts are the result of applying different ICMS rates and of refunds of ICMS-ST (the Substitute Taxpayer Regime). The respective tax credits have been progressively consumed. Since April 1, 2026, perfumery, cosmetics and personal care products are no longer subject to
substitute taxpayer regime, in accordance with Ordinance SRE 09/2025 (State Official Gazette DOE 12/23/2025).

Expected realization of credits

The expected realization of amounts classified in current and non-current assets is as follows:

	Parent Company		Consolidated	
Expected realization	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
In the next 12 months	888,614	509,584	908,247	541,373
Between 13 and 24 months	44,628	42,535	44,628	70,281
Between 25 and 36 months	62,238	58,571	62,238	58,571
Between 37 and 48 months	59,597	56,165	59,597	56,165
Over 48 months	104,183	70,060	104,183	70,060
Total	**1,159,260**	**736,915**	**1,178,893**	**796,450**

10.Investments

At September 30, 2026, the Company's investment balances are presented below:

		Sept/26			Dec/25		
Investee	**Main activity**	**Interest (%)**	**Parent Company**	**Consolidated**	**Interest (%)**	**Parent Company**	**Consolidated**
Direct interest							
4Bio	Retail of special medicines	-	-	-	100.00%	976,676	-
RD Ventures FIP	Private equity investment fund	100.00%	159,060	-	100.00%	155,086	-
Stix Fidelidade	Platform of products and services for the accumulation and redemption of points	100.00%	68,230	-	33.33%	18,425	18,425
Dr. Cuco	Digital care platform focused on adherence to treatment	100.00%	10,936	-	100.00%	11,581	-
Impulso	Advisory and consultancy in advertising and marketing	100.00%	166,018	-	100.00%	143,523	-
Dose Certa + Cuidado	Management of Self-Care Home Treatments	100.00%	44,942	-	100.00%	44,688	-
Manipulação Raia Drogasil	Marketplace of Compounding Pharmacies	100.00%	24,522	-	100.00%	23,828	-
Kymberg	Pharmaceutical company specialized in the production of medicines	100.00%	16,361	-	100.00%	16,351	-
Indirect interest							
Labi	Healthtech focused on laboratory tests, tests, check-ups and vaccines.	24.67%	-	(1,212)	24.96%	-	1,038
Total			**490,069**	**(1,212)**		**1,390,158**	**19,463**
Reclassification to "Other liabilities", as provision for losses on investments			**-**	**1,212**		**-**	**-**
Classified as investments			**490,069**	**-**		**1,390,158**	**19,463**

Changes in investment balances presented in the interim financial information are shown below:

Changes in investments	4BIO	stix	RD VENTURES	impulso	CUCO HEALTH	dose certa	DROGASIL / Raia manipulação	Kymberg	RD LOG	Total
	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	
At January 1, 2025	**733,451**	**9,475**	**169,200**	**123,132**	**15,061**	**40,493**	**20,285**	**17,930**	**16**	**1,129,043**
Capital contribution	60,000	-	24,450	-	120	13,500	9,900	-	-	**107,970**
Write-off of investment	-	-	-	-	-	-	-	-	(6)	**(6)**
Equity in the results of subsidiaries	173,601	5,538	(3,249)	12,956	(3,324)	(7,154)	(7,075)	(2,349)	(10)	**168,934**
Restricted share compensation plan	(332)	-	-	(9)	-	-	-	-	-	**(341)**
At September 30, 2025	**966,720**	**15,013**	**190,401**	**136,079**	**11,857**	**46,839**	**23,110**	**15,581**	**-**	**1,405,600**
Capital contribution	-	-	-	-	-	-	2,800	1,500	-	**4,300**
Write-off of investment	-	-	-	-	-	-	-	-	-	**-**
Equity in the results of subsidiaries	9,956	3,412	(35,315)	7,444	(276)	(2,151)	(2,082)	(730)	-	**(19,742)**
Restricted share compensation plan	-	-	-	-	-	-	-	-	-	**-**
At December 31, 2025	**976,676**	**18,425**	**155,086**	**143,523**	**11,581**	**44,688**	**23,828**	**16,351**	**-**	**1,390,158**
Capital contribution	-	-	3,620	-	150	6,200	6,000	2,000	-	**17,970**
Business combinations	-	42,568	-	-	-	-	-	-	-	**42,568**
Equity in the results of subsidiaries	20,141	7,237	354	22,495	(795)	(5,946)	(5,306)	(1,990)	-	**36,190**
Write-off of investment	(8,320)	-	-	-	-	-	-	-	-	**(8,320)**
Transfer to assets held for sale	(988,497)	-	-	-	-	-	-	-	-	**(988,497)**
At September 30, 2026	**-**	**68,230**	**159,060**	**166,018**	**10,936**	**44,942**	**24,522**	**16,361**	**-**	**490,069**

For the purpose of calculating the equity in subsidiaries and associates, the Company adjusts the assets, liabilities and the respective changes in the result. At 4Bio they are adjusted based on the purchase price allocation determined at the acquisition date. The table below shows the effects on profit (loss) for the period of subsidiaries and associate for the purposes of determining the equity in the results of subsidiaries for the periods ended September 30, 2026 and December 31, 2025:

Changes in equity in the results of subsidiaries	4BIO	stix	RD VENTURES	impulso	cuco HEALTH	dose certa SafePill	DROGASIL Raia manipulação	Kymberg	RD LOG	**Total**
Profit (loss) for the period	183,762	8,950	(38,564)	20,400	(2,761)	(9,305)	(7,998)	(3,079)	(10)	**151,395**
Amortization of surplus value arising from business combination	(206)	-	-	-	(839)	-	(1,159)	-	-	**(2,204)**
Equity in the results of subsidiaries at 12/31/2025	**183,556**	**8,950**	**(38,564)**	**20,400**	**(3,600)**	**(9,305)**	**(9,157)**	**(3,079)**	**(10)**	**149,191**
Profit (loss) for the period	20,211	7,278	354	22,495	(166)	(5,946)	(4,436)	(1,990)	-	**37,800**
Amortization of surplus value arising from business combination [1]	(70)	(41)	-	-	(629)	-	(870)	-	-	**(1,610)**
Equity in the results of subsidiaries at 9/30/2026	**20,141**	**7,237**	**354**	**22,495**	**(795)**	**(5,946)**	**(5,306)**	**(1,990)**	**-**	**36,190**

[1] Equity in the results of subsidiaries at 4Bio was calculated until April, last period prior to signing the closing agreement of the disposal of the RD's former subsidiary.

Adjusted equity	stix	RD VENTURES	impulso	cuco	dose certa	DROGASIL / Raia	Kymberg	Sept/26
Investment at book value	67,090	159,060	166,154	(1,881)	10,960	6,282	3,663	**411,328**
Purchase price allocation (surplus value of assets)	1,140	-	-	2,321	-	5,844	-	**9,305**
Restricted share compensation plan	-	-	(136)	-	-	-	-	**(136)**
Total adjusted equity	**68,230**	**159,060**	**166,018**	**440**	**10,960**	**12,126**	**3,663**	**420,497**
Goodwill based on expected future profitability	-	-	-	10,496	33,982	12,396	12,698	**69,572**
Investment balance	**68,230**	**159,060**	**166,018**	**10,936**	**44,942**	**24,522**	**16,361**	**490,069**

Adjusted equity	4BIO	stix	RD VENTURES	impulso	cuco	dose certa	DROGASIL / Raia	Kymberg	Dec/25
Investment at book value	962,908	18,425	155,086	143,659	(1,236)	10,706	5,588	3,653	**1,298,789**
Purchase price allocation (surplus value of assets)	2,167	-	-	-	2,321	-	5,844	-	**10,332**
Deferred income tax liability on allocation adjustments	(821)	-	-	-	-	-	-	-	**(821)**
Restricted share compensation plan	(485)	-	-	(136)	-	-	-	-	**(621)**
Total adjusted equity	**963,769**	**18,425**	**155,086**	**143,523**	**1,085**	**10,706**	**11,432**	**3,653**	1,307,679
Goodwill based on expected future profitability	12,907	-	-	-	10,496	33,982	12,396	12,698	**82,479**
Investment balance	**976,676**	**18,425**	**155,086**	**143,523**	**11,581**	**44,688**	**23,828**	**16,351**	1,390,158

10.1. Business combinations

On May 19, 2026, RD and Companhia Brasileira de Distribuição "GPA" entered into a Share Purchase and Sale Agreement and Other Covenants in which RD acquired all the shares of STIX FIDELIDADE E INTELIGÊNCIA S.A "Stix" held by GPA.

Stix was founded in 2018 and has a noncontrolling interest (33.33%) held by RD Saúde since 2019, Stix operates in the structuring, development, operation and management of loyalty program organized in the form of a coalition that brings together several players and enables the accumulation, management, sale and redemption of loyalty points. The base value of the transaction was R$ 23,000 for the acquisition of 66.7% of the shares of Stix, with no price adjustments, and was paid in two installments: (i) R$ 2,300 on the date of signing the purchase and sale agreement (September 30, 2026); and (ii) 20,700 million two days after the closing of the transaction. In the statement of cash flows, the amount of R$ 2,300 paid to the former shareholder is presented under "Acquisition and capital contribution in investees".

On September 30, the suspensive conditions set out in the Agreement were properly fulfilled or waived, and the Parties consummated the Closing of the transaction. On July 2, 2026, RD settled the transaction with GPA.

Assets	Jun/26	Liabilities	Jun/26
Cash and cash equivalents	144,517	Suppliers	15,307
Trade receivables	63,116	Salaries and social charges	22,355
Recoverable taxes	4,160	Taxes and contributions	2,243
Other assets	6,036	Other liabilities	100,737
Deferred income tax and social contribution	7,737	Deferred revenue	69,270
Property, plant and equipment	601	**Total liabilities**	**209,912**
Intangible assets	45,856	**Net assets and liabilities**	**62,111**
Total assets	**272,023**	**Total liabilities and equity**	**272,023**

As required by CPC 15 (R1)/ IFRS 3 – Business Combinations, all identifiable assets acquired and liabilities assumed were measured and recognized at their respective fair values on the transaction closing date.

As a result of the detailed assessment carried out by an independent expert, the net fair value (preliminary) of the identifiable assets and liabilities assumed exceeded the total consideration transferred, generated a bargain purchase gain recorded in the statement of income under " Other operating income/(expenses)".

Before the final recognition of this gain, the Company's management reviewed the process for identification and measurement of all assets acquired and liabilities assumed, as well as the assessment of the consideration transferred, confirming that all related elements were properly reflected in the accounting records.

The table below summarizes the consideration transferred, the fair values of the assets acquired and liabilities assumed on the transaction date, and the resulting bargain purchase gain:

Consideration	23,000
Net assets and liabilities – Sept/26	62,111
Surplus value - Software - Useful life of 7 years	1,709
Net assets and liabilities assumed (66.7%)	42,568
Gain on bargain purchase	19,568

The acquisition was completed on June 30, on that date Stix became a wholly-owned subsidiary of RD and the Company started to consolidate the subsidiary's financial information.

11.Property, plant and equipment

11.1. Breakdown and changes

Fixed assets are broken down as follows:

		Parent Company					
		Sept/26			Dec/25		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	**32,124**	32,124	-	**32,124**
Buildings	2.5 - 2.7	69,837	(37,098)	**32,739**	69,837	(35,800)	**34,037**
Furniture, fittings and facilities	7.4 - 10	2,120,597	(987,263)	**1,133,334**	2,106,499	(1,037,949)	**1,068,550**
Machinery and equipment	7.1 - 15.8	1,278,975	(809,558)	**469,417**	1,240,407	(790,440)	**449,967**
Vehicles	20 - 23.7	230,090	(146,959)	**83,131**	219,295	(125,658)	**93,637**
Property improvements	13 - 20	3,887,347	(2,574,950)	**1,312,397**	3,454,570	(2,241,529)	**1,213,041**
Total		**7,618,970**	**(4,555,828)**	**3,063,142**	**7,122,732**	**(4,231,376)**	**2,891,356**

		Consolidated					
		Sept/26			Dec/25		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	**32,124**	32,124	-	**32,124**
Buildings	2.5 - 2.7	69,837	(37,098)	**32,739**	69,837	(35,800)	**34,037**
Furniture, fittings and facilities	7.4 - 10	2,131,221	(988,836)	**1,142,385**	2,118,609	(1,040,619)	**1,077,990**
Machinery and equipment	7.1 - 15.8	1,328,329	(832,991)	**495,338**	1,295,267	(812,391)	**482,876**
Vehicles	20 - 23.7	230,091	(146,960)	**83,131**	219,296	(125,659)	**93,637**
Property improvements	13 - 20	3,894,328	(2,577,564)	**1,316,764**	3,469,561	(2,247,345)	**1,222,216**
Total		**7,685,930**	**(4,583,449)**	**3,102,481**	**7,204,694**	**(4,261,814)**	**2,942,880**

Changes in the Parent Company's fixed assets are as follows:

Changes in cost	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/26
Land	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**
Buildings	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**
Furniture, fittings and facilities	**1,893,280**	191,426	(5,350)	959	**2,080,315**	101,738	(74,687)	(867)	**2,106,499**	210,968	(196,744)	(126)	**2,120,597**
Machinery and equipment	**1,127,256**	109,067	(15,119)	-	**1,221,204**	53,568	(34,365)	-	**1,240,407**	109,486	(70,918)	-	**1,278,975**
Vehicles	**213,150**	3,303	(1,428)	-	**215,025**	4,966	(696)	-	**219,295**	15,054	(4,259)	-	**230,090**
Property improvements	**2,917,284**	397,776	(9,135)	3,713	**3,309,638**	149,924	(2,219)	(2,773)	**3,454,570**	454,956	(20,975)	(1,204)	**3,887,347**
Total	**6,252,931**	**701,572**	**(31,032)**	**4,672**	**6,928,143**	**310,196**	**(111,967)**	**(3,640)**	**7,122,732**	**790,464**	**(292,896)**	**(1,330)**	**7,618,970**

Changes in accumulated depreciation	Jan 1/2025	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/26
Buildings	**(34,056)**	(1,308)	-	-	**(35,364)**	(436)	-	-	**(35,800)**	(1,298)	-	-	**(37,098)**
Furniture, fittings and facilities	**(939,408)**	(129,887)	3,540	(177)	**(1,065,932)**	(46,022)	73,538	467	**(1,037,949)**	(143,788)	194,517	(43)	**(987,263)**
Machinery and equipment	**(719,864)**	(88,544)	13,664	-	**(794,744)**	(29,686)	33,990	-	**(790,440)**	(89,118)	70,000	-	**(809,558)**
Vehicles	**(94,344)**	(25,030)	1,415	-	**(117,959)**	(8,394)	695	-	**(125,658)**	(25,335)	4,034	-	**(146,959)**
Property improvements	**(1,825,804)**	(310,440)	4,346	(1,267)	**(2,133,165)**	(111,795)	1,455	1,976	**(2,241,529)**	(349,998)	15,739	838	**(2,574,950)**
Total	**(3,613,476)**	**(555,209)**	**22,965**	**(1,444)**	**(4,147,164)**	**(196,333)**	**109,678**	**2,443**	**(4,231,376)**	**(609,537)**	**284,290**	**795**	**(4,555,828)**

Changes in the Consolidated fixed assets are as follows:

Changes in cost	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Additions by business combination	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/26
Land	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**	-	-	-	-	**32,124**
Buildings	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**	-	-	-	-	**69,837**
Furniture, fittings and facilities	**1,903,450**	191,834	(5,487)	959	**2,090,756**	103,407	(74,687)	(867)	**2,118,609**	212,004	105	(199,371)	(126)	**2,131,221**
Machinery and equipment	**1,171,390**	117,804	(15,388)	-	**1,273,806**	57,673	(36,212)	-	**1,295,267**	112,827	864	(80,629)	-	**1,328,329**
Vehicles	**213,151**	3,304	(1,428)	-	**215,027**	4,965	(696)	-	**219,296**	15,054	-	(4,259)	-	**230,091**
Property improvements	**2,925,729**	403,494	(9,452)	3,713	**3,323,484**	151,069	(2,219)	(2,773)	**3,469,561**	455,071	73	(29,173)	(1,204)	**3,894,328**
Total	**6,315,681**	**716,436**	**(31,755)**	**4,672**	**7,005,034**	**317,114**	**(113,814)**	**(3,640)**	**7,204,694**	**794,956**	1,042	**(313,432)**	**(1,330)**	**7,685,930**

Changes in accumulated depreciation	Jan 1/2025	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/25	Additions	Additions by business combination	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/26
Buildings	**(34,056)**	(1,308)	-	-	**(35,364)**	(436)	-	-	**(35,800)**	(1,298)	-	-	-	**(37,098)**
Furniture, fittings and facilities	**(941,315)**	(130,485)	3,587	(177)	**(1,068,390)**	(46,234)	73,538	467	**(1,040,619)**	(144,330)	(48)	196,204	(43)	**(988,836)**
Machinery and equipment	**(733,166)**	(94,906)	13,755	-	**(814,317)**	(32,071)	33,997	-	**(812,391)**	(96,048)	(373)	75,821	-	**(832,991)**
Vehicles	**(94,345)**	(25,030)	1,415	-	**(117,960)**	(8,394)	695	-	**(125,659)**	(25,335)	-	4,034	-	**(146,960)**
Property improvements	**(1,830,127)**	(311,535)	4,569	(1,267)	**(2,138,360)**	(112,415)	1,454	1,976	**(2,247,345)**	(351,243)	(11)	20,197	838	**(2,577,564)**
Total	**(3,633,009)**	**(563,264)**	**23,326**	**(1,444)**	**(4,174,391)**	**(199,550)**	**109,684**	**2,443**	**(4,261,814)**	**(618,254)**	**(432)**	**296,256**	**795**	**(4,583,449)**

11.2. Changes in the provision for pharmacies closure

The changes in the Parent Company's provision for pharmacies closure are shown below:

	Provision	Depreciation	Total properties
At January 1, 2025	**(4,672)**	**1,444**	**(3,228)**
Additions	(1,443)	1,112	(331)
Reversals	6,115	(2,556)	3,559
At September 30, 2025	**-**	**-**	**-**
Additions	(3,640)	2,443	(1,197)
Reversals	-	-	-
At December 31, 2025	**(3,640)**	**2,443**	**(1,197)**
Additions	(13,711)	8,320	(5,391)
Reversals	12,381	(7,525)	4,856
Changes, net	**(1,330)**	**795**	**(535)**
At September 30, 2026	**(4,970)**	**3,238**	**(1,732)**

12. Intangible assets

12.1. Breakdown and changes

	Average annual amortization rates (%)	Parent Company					
		Sept/26			Dec/25		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Key money	17 - 23.4	314,988	(280,524)	34,464	310,069	(273,566)	**36,503**
Software license and systems implementation	20	1,755,833	(998,904)	756,929	1,560,057	(793,471)	**766,586**
Goodwill on business acquisition – Vison	(i)	22,275	(2,387)	19,888	22,275	(2,387)	**19,888**
Goodwill on business acquisition – Raia	(i)	780,084	-	780,084	780,084	-	**780,084**
Trademarks with finite useful life	20	9,311	(1,650)	7,661	18,453	(10,619)	**7,834**
Trademarks with indefinite useful life	(i)	151,000	-	151,000	151,000	-	**151,000**
Customers portfolio (Raia S.A.)	6.7 - 25	41,700	(41,662)	38	41,700	(41,317)	**383**
Total		**3,075,191**	**(1,325,127)**	**1,750,064**	**2,883,638**	**(1,121,360)**	**1,762,278**

	Average annual amortization rates (%)	Consolidated					
		Sept/26			Dec/25		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Key money	17 - 23.4	314,988	(280,525)	**34,463**	311,966	(273,563)	**38,403**
Software license and systems implementation	20	1,910,175	(1,087,337)	**822,838**	1,605,236	(812,643)	**792,593**
Goodwill on acquisitions of investees	(i)	1,025,032	(2,387)	**1,022,645**	1,050,593	(2,387)	**1,048,206**
Platform	20	8,886	(2,045)	**6,841**	8,886	(2,045)	**6,841**
Non-compete agreement	20	363	(363)	**-**	833	(345)	**488**
Trademarks with finite useful life	20	12,679	(4,746)	**7,933**	29,344	(19,868)	**9,476**
Trademarks with indefinite useful life	(i)	151,000	-	**151,000**	151,000	-	**151,000**
Customers portfolio (Raia S.A.)	6.7 - 25	41,700	(41,662)	**38**	41,700	(41,317)	**383**
Customer relationship	20	37,824	(6,991)	**30,833**	9,395	(5,222)	**4,173**
Total		**3,502,647**	**(1,426,056)**	**2,076,591**	**3,208,953**	**(1,157,390)**	**2,051,563**

(i) Assets with indefinite useful lives

Changes in the Company's intangible assets are as follows:

Changes in cost	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/26
Key money	**296,437**	10,726	(35)	35	**307,163**	2,959	(18)	(35)	**310,069**	10,102	(4,564)	(619)	**314,988**
Software license and systems implementation	**1,322,318**	225,350	(1,533)	-	**1,546,135**	107,829	(93,907)	-	**1,560,057**	195,776	-	-	**1,755,833**
Goodwill on business acquisition – Vison	**22,275**	-	-	-	**22,275**	-	-	-	**22,275**	-	-	-	**22,275**
Goodwill on business acquisition – Raia	**780,084**	-	-	-	**780,084**	-	-	-	**780,084**	-	-	-	**780,084**
Trademarks with finite useful life	**22,232**	-	(7,036)	-	**15,196**	-	3,257	-	**18,453**	-	(9,142)	-	**9,311**
Trademarks with indefinite useful life	**151,000**	-	-	-	**151,000**	-	-	-	**151,000**	-	-	-	**151,000**
Customers portfolio	**41,700**	-	-	-	**41,700**	-	-	-	**41,700**	-	-	-	**41,700**
Total	**2,636,046**	**236,076**	**(8,604)**	**35**	**2,863,553**	**110,788**	**(90,668)**	**(35)**	**2,883,638**	**205,878**	**(13,706)**	**(619)**	**3,075,191**

Changes in accumulated amortization	Jan 1/2025	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/25	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/26
Key money	**(256,434)**	(12,979)	17	(15)	**(269,411)**	(4,187)	5	27	**(273,566)**	(11,985)	4,408	619	**(280,524)**
Software license and systems implementation	**(592,881)**	(175,238)	235	-	**(767,884)**	(79,688)	54,101	-	**(793,471)**	(205,433)	-	-	**(998,904)**
Goodwill on business acquisition – Vison	**(2,387)**	-	-	-	**(2,387)**	-	-	-	**(2,387)**	-	-	-	**(2,387)**
Trademarks with finite useful life	**(14,163)**	(534)	3,793	-	**(10,904)**	285	-	-	**(10,619)**	(173)	9,142	-	**(1,650)**
Customers portfolio	**(40,857)**	(345)	-	-	**(41,202)**	(115)	-	-	**(41,317)**	(345)	-	-	**(41,662)**
Total	**(906,722)**	**(189,096)**	**4,045**	**(15)**	**(1,091,788)**	**(83,705)**	**54,106**	**27**	**(1,121,360)**	**(217,936)**	**13,550**	**619**	**(1,325,127)**

Changes in the Consolidated intangible assets are as follows:

Changes in cost	Jan 1/2025	Additions	Transfer	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Additions by business combination	Transfer	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/26
Key money	298,334	10,726	-	(35)	35	309,060	2,959	(18)	(35)	311,966	10,101	-	(1,897)	(4,563)	(619)	314,988
Software license and systems implementation	1,354,161	232,289	8,422	(1,603)	-	1,593,269	122,050	(110,083)	-	1,605,236	206,101	118,285	13,344	(32,791)	-	1,910,175
Goodwill on acquisitions of investees	1,059,015	-	(8,422)	-	-	1,050,593	-	-	-	1,050,593	-	-	2	(25,563)	-	1,025,032
Surplus value - Platform	8,886	-	-	-	-	8,886	-	-	-	8,886	-	-	-	-	-	8,886
Non-compete agreement	833	-	-	-	-	833	-	-	-	833	-	-	(470)	-	-	363
Trademarks with finite useful life	33,123	-	-	(7,036)	-	26,087	-	3,257	-	29,344	-	-	(5,479)	(11,186)	-	12,679
Trademarks with indefinite useful life	151,000	-	-	-	-	151,000	-	-	-	151,000	-	-	-	-	-	151,000
Customers portfolio - Raia	41,700	-	-	-	-	41,700	-	-	-	41,700	-	-	-	-	-	41,700
Customer relationship	9,395	-	-	-	-	9,395	-	-	-	9,395	37,000	-	(5,505)	(3,066)	-	37,824
Total	**2,956,447**	**243,015**	**-**	**(8,674)**	**35**	**3,190,823**	**125,009**	**(106,844)**	**(35)**	**3,208,953**	**253,202**	**118,285**	**(5)**	**(77,169)**	**(619)**	**3,502,647**

Changes in accumulated amortization	Jan 1/2025	Additions	Transfer	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Sept/25	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/25	Additions	Additions by business combination	Transfer	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Sept/26
Key money	(256,431)	(12,979)	-	17	(15)	(269,408)	(4,187)	5	27	(273,563)	(11,985)	-	(3)	4,407	619	(280,525)
Software license and systems implementation	(602,995)	(178,616)	-	235	-	(781,376)	(86,773)	55,506	-	(812,643)	(211,132)	(71,271)	(6,239)	13,948	-	(1,087,337)
Goodwill on acquisitions of investees	(2,387)	-	-	-	-	(2,387)	-	-	-	(2,387)	-	-	-	-	-	(2,387)
Surplus value - Platform	(1,647)	(299)	-	-	-	(1,946)	(99)	-	-	(2,045)	-	-	-	-	-	(2,045)
Non-compete agreement	-	-	-	-	-	-	(345)	-	-	(345)	(18)	-	-	-	-	(363)
Trademarks with finite useful life	(22,334)	(941)	-	3,793	-	(19,482)	(386)	-	-	(19,868)	(174)	-	4,432	10,864	-	(4,746)
Customers portfolio - Raia	(40,857)	(345)	-	-	-	(41,202)	(115)	-	-	(41,317)	(345)	-	-	-	-	(41,662)
Customer relationship	(4,192)	(154)	-	-	-	(4,346)	(876)	-	-	(5,222)	(6,167)	-	1,815	2,583	-	(6,991)
Total	**(930,843)**	**(193,334)**	**-**	**4,045**	**(15)**	**(1,120,147)**	**(92,781)**	**55,511**	**27**	**(1,157,390)**	**(229,821)**	**(71,271)**	**5**	**31,802**	**619**	**(1,426,056)**

12.2. Goodwill on the acquisition of companies

Goodwill on the acquisition of companies is subject to annual impairment testing.

Company	Goodwill amount	Acquisition
Drogaria Vison Ltda.	19,888	2/13/2008
Raia S.A.	780,084	11/10/2011
Dr. Cuco Desenvolvimento de Software Ltda.	10,496	11/19/2021
Healthbit Performasys Tecnologia Inteligência S.A.	17,505	3/09/2021
Amplisoftware Tecnologia Ltda.	82,895	12/22/2021
Labi Exames S.A.	52,328	8/05/2022
SafePill Comércio Varejista de Medicamentos Manipulados Ltda.	33,982	11/23/2022
ZTO Tecnologia e Serviços de Informação na Internet Ltda.	12,396	11/28/2022
Healthbit Serviços Médicos Ltda.	98	2/27/2023
Raia Drogasil Farmácia e Manipulação Ltda.	275	2/28/2023
Kymberg Farmacêutica do Brasil Ltda.	12,698	10/02/2023

The Company reviewed the criteria used to assess the impairment test as of December 31, 2025, and concluded that no events had occurred that would indicate impairment or the need for a new assessment as of September 30, 2026.

12.3. Changes in the provision for pharmacies closure

The changes in the Parent Company's provision for pharmacies closure are shown below:

	Provision	Amortization	Total intangible assets
At January 1, 2025	**(35)**	**15**	**(20)**
Additions	-	-	-
Reversals	35	(15)	20
At September 30, 2025	**-**	**-**	**-**
Additions	(35)	27	(8)
Reversals	-	-	-
At December 31, 2025	**(35)**	**27**	**(8)**
Additions	(1,470)	1,310	(160)
Reversals	851	(691)	160
Changes, net	**(619)**	**619**	**-**
At September 30, 2026	**(654)**	**646**	**(8)**

13.Employee benefits

(a) Profit sharing program

The Group has a profit sharing and bonus program intended mainly to measure the performance of employees during the year. Both programs have a formal plan and the amounts payable may be reasonably estimated before the information preparation period, and settled in the short term. On a monthly basis, a liability and an expense for profit sharing are recognized in the statement of income based on estimates of achievement of operating targets and specific objectives established and approved by Management. The recognition as liabilities is made in the account of salaries and social charges and in the statement of income the recognition is made in the accounts of selling expenses and general and administrative expenses (Note 23).

(b) Other benefits

Other short-term benefits are also granted to employees, such as life insurance, health and dental care, housing allowance, funeral assistance, maternity leave and scholarship, which are recognized on an accrual basis and whose right is extinguished at the end of the employment relationship with the Group. The Group does not grant post-employment benefits such as "Plano Gerador de Benefício Livre" (PGBL), "Vida Gerador de Benefício Livre" (VGBL), defined benefit pension plan and/or any retirement or post-employment assistance plan, severance pay benefits or other long-term benefits. Part of the benefits granted to the officers include a restricted share plan, classified as an equity instrument. The fair value of share-based payments is recognized in profit or loss in accordance with the granting period, against equity (see Note 21 d).

14.Suppliers

14.1. Balance breakdown

	Parent Company		Consolidated	
Supplier items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Goods suppliers	5,757,131	6,033,798	5,592,342	6,291,086
Service providers	424,145	419,854	492,941	424,334
Materials suppliers	44,004	51,031	44,004	51,255
Assets suppliers	25,522	25,576	25,522	26,002
Adjustment to present value	(77,975)	(104,510)	(77,975)	(112,027)
Total	**6,172,827**	**6,425,749**	**6,076,834**	**6,680,650**

14.2. Suppliers

The Company maintains an arrangement with RD FIDC that allows suppliers to discount their receivables from RD directly with RD FIDC and obtain early liquidity, while RD Saúde remains responsible for settling the notes on the date originally agreed upon with each supplier. In the parent company, the amount of R$ 169,108 (R$ 245,561 in 2025) remained recorded under "Goods suppliers" at September 30, 2026.

At September 30, 2026, the Company had not entered into any forfait transactions with financial institutions.
The Company's Management, based on NBC TG 03 (R3) - Statement of Cash Flows and NBC TG 40 (R2) - Financial Instruments: Disclosures, considered the qualitative aspects on the issue and concluded that there are no significant impacts since the economic substance of the transaction is maintained as an operating activity and there are no changes in the conditions originally agreed with suppliers, such as in the original maturities and amounts.

In the consolidated interim financial information, these amounts are classified as "Liabilities with senior quotaholders - FIDC," as they represent financial obligations to the holders of senior quotas in RD FIDC, as described in Note 15.

15.Liabilities with senior shareholders

The RD FIDC was established on February 16, 2023, for an indefinite term, with the objective of facilitating the advance of receivables from the Company's suppliers through the assignment of receivable rights directly to the fund. The transaction allows suppliers to obtain early liquidity, while RD Saúde remains responsible for settling the notes on the date originally agreed upon with each supplier. The Company, in turn, receives a portion of the discount from the transaction. This revenue totaled R$ 5,260 for the nine-month period ended September 30, 2026 (R$ 4,813 in Sept/2025) and is recorded under general and administrative expenses, in accordance with the supplier's classification. Senior quotas rose by R$ 9,436 during the period (R$ 8,758 in Sept/2025).

In the operational structure of advance of receivables:

The credit risk considered is that of the Company itself;
The terms and conditions originally agreed upon with the suppliers remain unchanged following the assignment to the FIDC;
There are no additional obligations or financial costs for the Company arising from this transaction.

At September 30, 2026, the balance of senior quotas totaled R$ 253,375 (R$ 218,895 - Sept/2025).

These amounts are classified as "Liabilities with senior quotaholders - FIDC," as they represent financial obligations to the holders of senior quotas in RD FIDC. Cash flows related to contributions and redemptions of quotas, as well as the payment of remuneration to senior quotaholders, are presented as financing activities in the Statement of Cash Flows. The Company reviewed the covenants in its existing loan and financing agreements and concluded that the outstanding balance of liabilities with senior quotaholders is not included in the Company's net debt at September 30, 2026.

16.Borrowings and debentures

(a) Breakdown

		Parent Company		Consolidated	
Borrowings items	**Average annual long-term interest rate**	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Debentures					
3rd issue of debentures - CRIs	98.50% of CDI	-	129,940	-	129,940
4th issue of debentures	106.99% of CDI	156,241	301,501	156,241	301,501
5th issue of debentures	100.00% of CDI + 1.49% p.a.	512,764	534,153	512,764	534,153
6th issue of debentures - CRIs	100.00% of CDI + 0.70% p.a.	125,621	260,579	125,621	260,579
7th issue of debentures - CRIs	100.00% of CDI + 0.75% p.a.	564,922	543,732	564,922	543,732
8th issue of debentures - CRIs – 2nd series	100.00% of CDI + 0.65% p.a.	150,255	155,494	150,255	155,494
8th issue of debentures - CRIs – 3rd series	100.00% of CDI + 1.10% p.a.	196,225	203,173	196,225	203,173
9th issue of debentures	100.00% of CDI + 0.65% p.a.	636,898	615,366	636,898	615,366
10th issue of debentures	100.00% of CDI + 0.60% p.a.	531,673	514,080	531,673	514,080
11th issue of debentures	100.00% of CDI + 0.44% p.a.	631,282	609,737	631,282	609,737
Total debentures		**3,505,881**	**3,867,755**	**3,505,881**	**3,867,755**
Current liabilities		417,270	508,137	417,270	508,137
Non-current liabilities		3,088,611	3,359,618	3,088,611	3,359,618

The amounts above have the following payment flow forecast:

	Parent Company		Consolidated	
Payment forecast	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
2026	129,718	508,137	129,718	508,137
2027	436,442	419,898	436,442	419,898
2028	520,560	520,559	520,560	520,559
2029 and thereafter	2,419,161	2,419,161	2,419,161	2,419,161
Total	**3,505,881**	**3,867,755**	**3,505,881**	**3,867,755**

(b) Characteristics of the debentures

Debentures

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
4th issue – Single Series	R$ 300,000	300,000	6/17/2019	Jun/2027	106.99% of CDI	R$ 1
5th issue – Single Series	R$ 500,000	500,000	1/25/2022	Jan/2029	100% of CDI + 1.49% p.a.	R$ 1
6th issue – Single Series	R$ 250,000	250,000	3/07/2022	Mar/2027	100% of CDI + 0.70% p.a.	R$ 1
7th issue – Single Series	R$ 550,000	550,000	6/26/2022	Jun/2029	100% of CDI + 0.75% p.a.	R$ 1
8th issue - 2nd series	R$ 150,000	150,000	9/15/2023	Sept/2027	100% of CDI + 0.65% p.a.	R$ 1
8thissue - 3rd series	R$ 200,000	200,000	9/15/2023	Sept/2030	100% of CDI + 1.10% p.a.	R$ 1
9th issue – Single Series	R$ 600,000	600,000	4/22/2024	Apr/2031	100% of CDI + 0.65% p.a.	R$ 1
10th issue – Single Series	R$ 500,000	500,000	4/15/2025	Apr/2032	100% of CDI + 0.60% p.a.	R$ 1
11th issue – Single Series	R$ 600,000	600,000	11/10/2025	Nov/2032	100% of CDI + 0.44% p.a.	R$ 1

(*) Weighted average rate of series.

On June 17, 2019, the Company carried out the 4th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on July 12, 2019, in the amount of R$ 300,000, with remuneration of 106.99% of CDI and payment term of eight years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 17, 2027. The funds were used to improve the working capital.

On January 25, 2022, the Company carried out the 5th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on February 16, 2022, in the amount of R$ 500,000, with remuneration of 100% of CDI, plus a surcharge of 1.49% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on January 25, 2029. The funds were used to improve the working capital.

On March 7, 2022, the Company carried out the 6th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on March 17, 2022, in the amount of R$ 250,000, with remuneration of 100% of CDI, plus a surcharge of 0.70% per year, and payment term of five years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on March 8, 2027. The funds raised were used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 476.

On June 26, 2022, the Company carried out the 7th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 476), with settlement on June 29, 2022, in the amount of R$ 550,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.75% per year, and payment term of five years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 25, 2029. The funds raised will be used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 476.

On September 15, 2023, the Company carried out the 8th issue of non-convertible, simple unsecured debentures, in three series, for public distribution with firm placement guarantee, pursuant to CVM Resolutions No. 160 and No. 60, as well as other applicable legal and regulatory provisions, with settlement on September 15, 2023, in the amounts of R$ 350,000 for the 1st series, R$ 150,000 for the 2nd series and R$ 200,000 for the 3rd series, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.30% p.a. for the 1st series, 0.65% p.a. for the 2nd series, and 1.10% p.a. for the 3rd series, with payment term of two, four and seven years, respectively. Interest payments will be semi-annual, and principal will be amortized for the 1st series on September 11, 2025, for the 2nd series on September 13, 2027, and for the 3rd series in two equal annual and consecutive installments, the last installment to be paid on September 12, 2030. The funds raised were used for real estate costs and expenses referring to the payment of rentals of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Resolutions 160 and 60.

On April 22, 2024, the Company carried out the 9th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 160), with settlement on May 3, 2024, in the amount of R$ 600,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.65% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on April 22, 2031. The funds were used to strengthen cash.

On April 15, 2025, the Company carried out the 10th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 160), with settlement on April 17, 2025, in the amount of R$ 500,000, with remuneration of 100% of DI, plus a surcharge of 0.60% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on April 15, 2032. The funds were used to strengthen cash.

On November 10, 2025, the Company carried out the 11th issue of non-convertible, simple unsecured debentures, in a single series, for public distribution with restricted efforts (CVM 160), with settlement on November 10, 2025, in the amount of R$ 600,000, with remuneration of 100% of DI, plus a surcharge of 0.44% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on November 10, 2032. The funds were used to strengthen cash.

The costs incurred on the issues of the Company's debentures (2019 - 4th issue, 2022 - 5th, 6th and 7th issues, 2023 - 8th issue, 2024 - 9th issue and 2025 - 10th and 11thissues), including fees, commissions and other costs are classified in the line item of the respective debentures, and will be recognized over the total period of the debt. At September 30, 2026, the amount to be recognized was R$ 17,053 (R$ 21,991 – Dec/2025), and is presented net in debentures balance.

The Company's debentures are conditioned to the compliance with the following covenants:

(i) Net Debt / EBTIDA: cannot exceed 3 times.

The calculation of net debt, the basis for determining the covenants calculation of Company's debentures, considers the balances of borrowings. As described in Note 26.2 (e), the lease obligations are being presented in a separate line item in the Interim Financial Information, and therefore are not included in the net debt calculation.

Covenants are measured quarterly and, at September 30, 2026, the Company was in compliance with such requirements.

The non-compliance with the covenants for two consecutive quarters can be considered as a default event and consequently result in early maturity.

The Group monitors clauses subject to compliance with financial and non-financial covenants, in order to ensure that they are being complied with. At September 30, 2026, the Company was in compliance with these covenants.

Reconciliation of net debt

The analysis of and the changes in net debt are presented below:

	Parent Company		Consolidated	
Composition and changes in net debt	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Short-term borrowings	417,270	508,137	417,270	508,137
Long-term borrowings	3,088,611	3,359,618	3,088,611	3,359,618
Total debt	**3,505,881**	**3,867,755**	**3,505,881**	**3,867,755**
(-) Cash and cash equivalents (Note 5)	(270,859)	(296,965)	(503,985)	(509,619)
Net debt	**3,235,022**	**3,570,790**	**3,001,896**	**3,358,136**

	Parent Company		
Changes in net debt	**Borrowings**	**Cash and cash equivalents**	**Net debt**
Net debt at January 1, 2025	**3,204,348**	**(460,292)**	**2,744,056**
Funding	500,000	-	500,000
Accrued interest	360,406	-	360,406
Payment of interest	(311,739)	-	(311,739)
Amortization of principal	(475,000)	-	(475,000)
Transaction cost – net	4,598	-	4,598
Increase in cash and cash equivalents	-	180,962	180,962
Net debt at September 30, 2025	**3,282,613**	**(279,330)**	**3,003,283**
Funding	600,000	-	600,000
Accrued interest	135,149	-	135,149
Payment of interest	(149,444)	-	(149,444)
Amortization of principal	-	-	-
Transaction cost – net	(563)	-	(563)
Decrease in cash and cash equivalents	-	(17,635)	(17,635)
Net debt at December 31, 2025	**3,867,755**	**(296,965)**	**3,570,790**
Accrued interest	387,416	-	387,416
Payment of interest	(354,228)	-	(354,228)
Amortization of principal	(400,000)	-	(400,000)
Transaction cost – net	4,938	-	4,938
Increase in cash and cash equivalents	-	26,106	26,106
Net debt at September 30, 2026	**3,505,881**	**(270,859)**	**3,235,022**

	Consolidated		
Changes in net debt	Borrowings	Cash and cash equivalents	Net debt
Net debt at January 1, 2025	**3,293,930**	**(528,002)**	**2,765,928**
Funding	590,000	-	590,000
Accrued interest	360,943	-	360,943
Charges on borrowings	7,400	-	7,400
Payment of interest	(320,389)	-	(320,389)
Amortization of principal	(653,869)	-	(653,869)
Transaction cost – net	4,598	-	4,598
Increase in cash and cash equivalents	-	91,662	91,662
Net debt at September 30, 2025	**3,282,613**	**(436,340)**	**2,846,273**
Funding	600,000	-	600,000
Accrued interest	135,149	-	135,149
Charges on borrowings	-	-	-
Payment of interest	(149,444)	-	(149,444)
Amortization of principal	-	-	-
Transaction cost – net	(563)	-	(563)
Increase in cash and cash equivalents	-	(73,279)	(73,279)
Net debt at December 31, 2025	**3,867,755**	**(509,619)**	**3,358,136**
Accrued interest	387,416	-	387,416
Payment of interest	(354,228)	-	(354,228)
Amortization of principal	(400,000)	-	(400,000)
Transaction cost – net	4,938	-	4,938
Decrease in cash and cash equivalents	-	5,634	5,634
Net debt at September 30, 2026	**3,505,881**	**(503,985)**	**3,001,896**

17.Leases

As a lessee

Right-of-use assets

Breakdown of Parent Company and Consolidated right-of-use assets:

	Parent Company		Consolidated	
Right-of-use assets	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Operating real estate	4,044,297	3,807,070	4,045,335	3,808,354
Residential real estate	53,961	50,585	53,960	50,807
Distribution centers and administrative properties	497,602	464,181	497,602	469,476
Vehicles	24,638	7,410	24,639	7,411
Total	**4,620,498**	**4,329,246**	**4,621,536**	**4,336,048**

The changes in the Parent Company and Consolidated right-of-use assets are presented below:

	Parent Company				
	Operating real estate	**Residential real estate**	**Distribution/ administrative centers**	**Vehicles**	**Total**
At 01/01/2025	**3,418,181**	**27,357**	**429,704**	**6,325**	**3,881,567**
New agreements	466,473	12,106	391	-	478,970
Remeasurements (i)	578,807	22,850	71,286	3,304	676,247
Termination of agreements	(25,707)	(5,405)	-	-	(31,112)
Depreciation	(671,979)	(5,378)	(79,956)	(1,243)	(758,556)
At 09/30/2025	**3,765,775**	**51,530**	**421,425**	**8,386**	**4,247,116**
New agreements	104,143	2,238	744	169	107,294
Remeasurements (i)	171,930	(1,304)	69,948	(710)	239,864
Termination of agreements	-	-	-	-	-
Depreciation	(234,778)	(1,879)	(27,936)	(435)	(265,028)
At 12/31/2025	**3,807,070**	**50,585**	**464,181**	**7,410**	**4,329,246**
New agreements	470,269	9,184	28,104	13,194	520,751
Remeasurements (i)	503,429	5,819	93,029	4,413	606,690
Termination of agreements	(12,228)	(5,904)	-	-	(18,132)
Depreciation	(724,243)	(5,723)	(87,712)	(379)	(818,057)
At 09/30/2026	**4,044,297**	**53,961**	**497,602**	**24,638**	**4,620,498**

	Consolidated				
	Operating real estate	**Residential real estate**	**Distribution/ administrative centers**	**Vehicles**	**Total**
At 01/01/2025	**3,419,464**	**27,622**	**433,565**	**6,326**	**3,886,977**
New agreements	466,473	12,106	1,905	-	480,484
Remeasurements (i)	578,807	22,854	71,878	3,304	676,843
Termination of agreements	(25,707)	(5,438)	(480)	-	(31,625)
Depreciation	(671,979)	(5,392)	(81,719)	(1,243)	(760,333)
At 09/30/2025	**3,767,058**	**51,752**	**425,149**	**8,387**	**4,252,346**
New agreements	104,143	2,238	2,791	169	109,341
Remeasurements (i)	171,930	(1,304)	69,992	(710)	239,908
Termination of agreements	-	-	(30)	-	(30)
Depreciation	(234,777)	(1,879)	(28,426)	(435)	(265,517)
At 12/31/2025	**3,808,354**	**50,807**	**469,476**	**7,411**	**4,336,048**
New agreements	471,667	9,184	28,104	13,194	522,149
Remeasurements (i)	503,427	5,819	93,248	4,413	606,907
Termination of agreements	(12,228)	(5,904)	-	-	(18,132)
Depreciation	(724,602)	(5,723)	(88,242)	(379)	(818,946)
Write-off due to sale of investee	(1,283)	(223)	(4,984)	-	(6,490)
At 09/30/2026	**4,045,335**	**53,960**	**497,602**	**24,639**	**4,621,536**

(i) The Company remeasures the right-of-use assets in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases), initially determined as short-term contracts.

Lease liabilities

The changes in the Parent Company and Consolidated lease liabilities are as follows:

	Parent Company	Consolidated
At 01/01/2025	**4,418,993**	**4,424,537**
New agreements	478,970	480,484
Remeasurements (i)	676,246	676,842
Termination of agreements	(42,366)	(43,039)
Interest	355,905	356,353
Payments / compensations	(1,028,318)	(1,030,278)
At 09/30/2025	**4,859,430**	**4,864,899**
New agreements	107,294	109,341
Remeasurements (i)	239,864	239,908
Termination of agreements	(708)	(578)
Interest	122,145	122,263
Payments / compensations	(368,794)	(369,521)
At 12/31/2025	**4,959,231**	**4,966,312**
New agreements	520,751	522,157
Remeasurements (i)	606,692	606,908
Termination of agreements	(23,648)	(23,648)
Interest	415,950	416,307
Payments / compensations	(1,153,332)	(1,154,462)
Write-off due to sale of investee	-	(6,822)
At 09/30/2026	**5,325,644**	**5,326,752**

(i) The Company remeasures the lease liabilities in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases).

The maturities of lease liabilities are classified according to the following schedule:

	Parent Company		Consolidated	
Analysis of maturities - Lease liabilities	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Less than 1 year	1,039,306	1,019,344	1,039,767	1,021,147
Current	**1,039,306**	**1,019,344**	**1,039,767**	**1,021,147**
1 to 5 years	3,204,855	2,971,403	3,205,502	2,976,681
Over 5 years	1,081,483	968,484	1,081,483	968,484
Non-current	**4,286,338**	**3,939,887**	**4,286,985**	**3,945,165**
Total	**5,325,644**	**4,959,231**	**5,326,752**	**4,966,312**

Future payments to be made to the lessor may give the Group the right to be credited with PIS and COFINS. Therefore, the recorded amount of the right-of-use asset against the lease liability already includes potential future credit.

The potential right to PIS and COFINS recoverable embedded in future lease payments is presented below:

Future considerations	**Parent Company**	**Potential PIS / COFINS (9.25%)**
Less than 1 year	1,039,843	96,185
1 to 2 years	902,300	83,463
2 to 3 years	740,971	68,540
3 to 4 years	598,336	55,346
4 to 5 years	475,618	43,995
Over 5 years	1,287,421	119,086
Total	**5,044,489**	**466,615**

The right to use PIS and COFINS credits comprises only contracts whose lessor is a legal entity. The Company has lease contracts for both lessors, corporate and individual.

In compliance with CVM Circular Letter 02/2019 and NBC TG 06 (R3) / IFRS 16, justified by the fact that the Group has not applied the methodology of nominal flows due to the prohibition imposed by NBC TG 06 (R3) of future inflation projection and in order to provide additional information to the users of the Group's financial statements, the analysis of contract maturities and installments not yet discounted at September 30, 2026 is presented below:

	Parent Company			Consolidated		
Year	Amounts of installments not yet discounted	Estimated interest (future) (i)	Net present value	Amounts of installments not yet discounted	Estimated interest (future) (i)	Net present value
2026	401,439	(146,484)	254,955	401,900	(146,484)	255,416
2027	1,558,963	(522,959)	1,036,004	1,558,963	(522,959)	1,036,004
2028	1,330,450	(423,555)	906,895	1,331,097	(423,555)	907,542
2029	1,046,543	(335,229)	711,314	1,046,543	(335,229)	711,314
2030	866,581	(261,991)	604,590	866,581	(261,991)	604,590
2031 and thereafter	2,371,678	(559,792)	1,811,886	2,371,678	(559,792)	1,811,886
Total	**7,575,654**	**(2,250,010)**	**5,325,644**	**7,576,762**	**(2,250,010)**	**5,326,752**

(i) The present value of the leases payable was calculated considering the projection of future fixed payments, discounted at the rate of 14.79% p.a. (15.77% p.a. – Dec/25), which was built from the basic interest rate released by the Central Bank of Brazil (BACEN).

Amount recognized in the statement of income

	Parent Company		Consolidated	
Amount recognized in the statement of income	Sept/26	Sept/25	Sept/26	Sept/25
Depreciation of right-of-use assets	818,057	758,556	818,946	756,779
Interest on lease liabilities	415,950	355,905	416,307	356,353
Adjustment for lease write-off (contracts terminated)	(3,932)	(6,028)	(3,932)	(6,028)
Variable payments not included in the measurement of lease liabilities	47,306	41,509	47,306	42,551
Revenue on subleases of right-of-use assets	(3,695)	3,336	(3,695)	3,336
Expenses related to short-term and/or low-value leases	13,202	18,974	13,202	18,974

(i) Payment of variable leases based on sales

Some operating real estate leases contain variable lease payments based on a percentage of 2% to 12% of the sales made during the period in the leased operating real estate. These payment conditions are common for stores in the country where the Group operates. Variable lease payments for the period ended September 30, 2026 amounted to R$ 11,495 (R$ 7,651 in Dec/25) for Parent Company and consolidated accounts.

(ii) Leases fitting into exceptions and practical expedients

The lease agreements identified and that fall within the scope of exemption mainly refer to lease of printers, forklifts, scales, power generators, electron aligners and photovoltaic plates.

The Group also leases equipment with contracts of up to one year. These leases are short-term and/or low-value leases. The Group opted not to recognize the right-of-use assets and the lease liabilities of such items.

As a lessor

The Group subleases some of the properties to third parties. The Group has classified these leases as operating leases because they do not transfer substantially all the risks and rewards of ownership of assets.

The table below presents an analysis of maturities of lease payments, showing undiscounted lease payments to be received after the reporting date:

	Parent Company and Consolidated	
Undiscounted lease payments	**Sept/26**	**Dec/25**
Less than 1 year	2,119	1,401
1 to 2 years	2,008	1,438
2 to 3 years	1,957	1,438
3 to 4 years	1,314	1,375
4 to 5 years	339	61
Over 5 years	19	127
Total	**7,756**	**5,840**

18.Provision for contingencies and judicial deposits

Breakdown of balances and changes in provisions

At September 30, 2026, the Group had the following provisions and corresponding judicial deposits relating to legal proceedings:

	Parent Company		Consolidated	
Judicial deposit items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Labor and social security	135,057	153,897	135,067	154,359
Tax [(i)]	33,933	21,675	33,933	134,768
Civil	23,303	17,946	23,303	17,946
Total	**192,293**	**193,518**	**192,303**	**307,073**
Current liabilities	24,810	58,220	24,810	58,220
Non-current liabilities	167,483	135,298	167,493	248,853

(i) One of the Company's subsidiaries is a party to lawsuits challenging the payment of the differences in ICMS rates in certain states, recording judicial deposits for the amounts in dispute. In this context, up to the first quarter of 2022, the subsidiary adopted the practice of recording a provision for the judicial deposits. Considering the lawsuits with final and unappealable decisions favorable to the subsidiary, occurred during the first quarter of 2022, and the withdrawal of the deposits, it was decided, after the assessment of the external advisors, that the provision for the deposited amounts would be reversed in March 2022. After the decision of the Federal Supreme Court (STF) on November 29, 2023, the subsidiary started to record a provision referring to the lawsuits challenging the payment of the ICMS- DIFAL in certain states, considering the judicial deposits made between April 2022 and December 2023.

On October 21, 2025, the Federal Supreme Court (STF), by majority vote, revised its previous decision and introduced the modulation of effects, ruling that taxpayers who filed lawsuits before November 29, 2023, and did not collect the tax cannot be charged the ICMS Rate Differential ("DIFAL") related to fiscal year 2022. In light of this decision, the Company reassessed the associated risks and reversed the provision previously recognized for this period, in the amount of R$ 70,098 (comprising R$ 55,760 in principal and R$ 14,338 in monetary adjustment).

Changes in the provision are as follows:

Changes in the contingencies	**Parent Company**	**Consolidated**
At January 1, 2025	**168,509**	**363,888**
Additions of new lawsuits and review of estimate	119,603	121,293
Write-offs for payments	(47,311)	(47,311)
Constitution/(Reversals) due to changes in lawsuits	(39,897)	(135,009)
Monetary adjustment	(9,286)	523
At September 30, 2025	**191,618**	**303,384**
Additions of new lawsuits and review of estimate	43,213	43,285
Write-offs for payments	(22,414)	(22,414)
Constitution/(Reversals) due to changes in lawsuits	(9,762)	(9,831)
Monetary adjustment	(9,137)	(7,351)
At December 31, 2025	**193,518**	**307,073**
Additions of new lawsuits and review of estimate	96,668	96,678
Write-offs for payments	(76,783)	(76,783)
Constitution/(Reversals) due to changes in lawsuits	(28,967)	(28,967)
Transfer to liabilities held for sale	-	(113,555)
Monetary adjustment	7,857	7,857
At September 30, 2026	**192,293**	**192,303**

The provision for legal claims took into consideration the best estimate of the amounts involved, for the cases in which the likelihood of loss is estimated as probable, remaining a portion of these claims guaranteed by pledged assets.

Possible losses

At September 30, 2026, the Group has tax lawsuits related to fines applied by the relevant administrative authorities, tax rate difference in interstate transfers and tax enforcements, as well as civil lawsuits due to indemnity claims for losses and pain and suffering arising from consumer relations, and sundry labor claims, involving possible loss as assessed by Management and its legal advisors in the amount of R$ 1,127,149 for the Parent Company and Consolidated (R$ 938,114 and R$ 1,003,604, respectively, in Dec/2025), of which R$ 907,695 for the Parent Company and Consolidated refer to tax lawsuits (R$ 820,040 for the Parent Company and R$ 885,530 for the Consolidated – Dec/2025), the total of R$ 126,925 refers to labor claims for the Parent Company and Consolidated (R$ 35,249 – Dec/2025) and the amount of R$ 92,529 for both the Parent Company and Consolidated corresponds to civil lawsuits (R$ 82,825 – Dec/2025).

Judicial deposits

At September 30, 2026, the Group had the following judicial deposit amounts, for which no corresponding provision had been set up:

	Parent Company		Consolidated	
Analysis of judicial deposits	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Labor and social security	12,099	10,529	12,125	10,669
Tax	49,221	49,937	49,221	284,887
Civil	6,998	5,730	6,998	5,763
Total	**68,318**	**66,196**	**68,344**	**301,319**
Current assets	3,027	4,970	3,027	4,970
Non-current assets	65,291	61,226	65,317	296,349

Labor contingencies

Most labor claims relate to lawsuits filed by former employees questioning the payment of unpaid overtime and health hazard premium. The Group is also involved in proceedings arising from Raia S.A., as well as from Drogaria Onofre Ltda., which were filed by former employees of service providers claiming to have employment relationships directly with the Group, or in which the Group received a joint enforcement order for the payment of the labor rights claimed. There are also proceedings filed by professional unions for the payment of union dues, under the dispute regarding the legitimacy of the territorial base.

Tax contingencies

These represent administrative fines, tax rate differences on interstate transfers and tax collection proceedings.

Civil contingencies

The Group is a defendant in lawsuits regarding usual and unique matters arising in the course of its business, most of which seek indemnification for property damage and pain and suffering from consumption relations.

Guarantees for lawsuits

The following items of fixed assets were given as guarantees for tax, social security and labor proceedings:

	Parent Company / Consolidated	
Guarantees for lawsuits	**Sept/26**	**Dec/25**
Machinery and equipment	85	85
Total guarantees for lawsuits	**85**	**85**

19.Income tax and social contribution

19.1. Breakdown of current income tax and social contribution and effective rate

	Parent Company		Consolidated	
Effective income tax and social contribution items	**Sept/26**	**Sept/25**	**Sept/26**	**Sept/25**
				Restated
Profit before income tax and social contribution	1,162,961	1,143,089	1,157,960	994,709
Interest on capital and additional interest on capital proposed	(464,700)	(390,600)	(464,700)	(390,600)
Taxable profit	**698,261**	**752,489**	**693,260**	**604,109**
Combined tax rate (25% for income tax and 9% for social contribution)	34%	34%	34%	34%
Theoretical tax expense	**(237,409)**	**(255,846)**	**(235,708)**	**(205,397)**
Permanent additions and/or exclusions	(17,418)	(12,905)	(24,819)	(13,256)
Equity in the results of subsidiaries	12,851	57,999	3,591	330
Investment grant(i)	30,228	15,574	30,228	15,573
Tax incentives — Lei do Bem	25,581	22,994	25,581	22,994
Tax incentives - Other incentives	18,454	19,076	18,454	19,076
Other	(3,491)	1,962	(3,491)	1,958
Result of current income tax and social contribution	**(203,995)**	**(213,994)**	**(219,553)**	**(219,715)**
Result of deferred income tax and social contribution	**32,791**	**62,848**	**33,389**	**60,993**
Income tax and social contribution expense	**(171,204)**	**(151,146)**	**(186,164)**	**(158,722)**
Effective tax rate	**14.72%**	**13.22%**	**16.08%**	**15.96%**

(i) Change in tax position of the treatment of the investment grant due to the new STJ precedent in September 2025, which recognized the undue inclusion of the presumed ICMS credit in the IRPJ and CSLL calculation basis, even after the new legislation came into force, as it constitutes a violation of the federative pact.

19.2. Deferred income tax and social contribution are comprised as follows:

Deferred income tax and social contribution assets amounting to R$ 540,168 in Sept/26 (R$ 507,494 – Dec/25) for the Parent Company and R$ 593,464 in Sept/26 (R$ 660,839 – Dec/25) for the Consolidated accounts arose from temporarily non-deductible expenses that may be carried forward indefinitely, with estimated realization as disclosed in item 19.3 below.

Deferred income tax and social contribution liabilities amounting to R$ 302,452 in Sept/26 (R$ 302,614 – Dec/25) for the Parent Company and R$ 302,454 in Sept/26 (R$ 303,352 – Dec/25) for the Consolidated accounts relate to tax charges on the remaining balances: (i) of the revaluation reserve.

In the periods ended September 30, 2026 and 2025, deferred income tax and social contribution were as follows:

	Balance sheet				Statement of income			
	Parent Company		Consolidated		Parent Company		Consolidated	
Temporary differences	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**	**Sept/26**	**Sept/25**	**Sept/26**	**Sept/25**
								Restated
Revaluation at fair value of land and buildings[i]	(6,383)	(6,429)	(6,384)	(7,167)	-	-	-	-
Amortization of the goodwill on future profitability [ii]	(243,010)	(243,008)	(243,010)	(243,008)	1	1	1	1
Non-deductible intangible assets	(53,060)	(53,177)	(53,060)	(53,177)	(117)	(117)	(117)	(117)
Tax losses to be offset against future taxable profits	-	-		153,345	-	-	3,420	2,000
Adjustment to present value	7,886	12,576	7,886	12,576	4,691	3,375	4,691	3,375
Provision for inventory losses	24,764	30,939	24,764	30,939	6,176	(12,825)	6,176	(12,825)
Provision for sundry obligations	122,226	93,525	122,226	93,525	(28,702)	(21,442)	(28,702)	(21,442)
Provision for employee profit sharing	24,590	41,123	24,590	41,123	16,533	10,866	16,533	10,866
Provision for contingencies	87,476	73,856	87,476	73,856	(13,620)	(19,309)	(13,620)	(19,309)
Expected credit losses	3,192	1,892	3,192	1,892	(1,299)	(359)	(1,299)	(359)
Lease (depreciation - asset)	3,003,393	2,585,167	3,003,393	2,585,167	(418,226)	(376,865)	(418,226)	(376,865)
Lease (consideration - liability)	(2,761,348)	(2,368,298)	(2,761,348)	(2,368,298)	393,050	348,866	393,050	348,866
Other adjustments	27,990	36,714	81,285	36,714	8,722	4,961	4,704	4,816
Deferred income tax and social contribution expense					**(32,791)**	**(62,848)**	**(33,389)**	**(60,993)**
Deferred tax assets, net	**237,716**	**204,880**	**291,010**	**357,487**				
Deferred tax liabilities, net	**-**	**-**	**-**	**-**				
Reflected in the balance sheet as follows:								
Deferred tax assets	540,168	507,494	593,464	660,839				
Deferred tax liabilities	(302,452)	(302,614)	(302,454)	(303,352)				
Deferred tax assets, net – Parent Company	**237,716**	**204,880**	**237,716**	**204,880**				
Deferred tax liabilities, net	**-**	**-**	**-**	**-**				
Deferred tax assets – Subsidiaries	**-**	**-**	**53,294**	**152,607**				
Reconciliation of deferred tax assets (liabilities), net								
Balance at the beginning of the year	204,880	141,278	357,487	298,405				
Expense recognized in the statement of income	32,791	63,538	33,389	58,949				
Asset held for sale	-	-	(107,591)	-				
Asset acquisition of control - Stix	-	-	7,680	-				
Realization of deferred tax recognized in equity	45	64	45	133				
Balance at the end of the period	**237,716**	**204,880**	**291,010**	**357,487**				

19.3. Estimated recovery of income tax and social contribution credits

The projections of future taxable profits are based on estimates relating to the Group's performance, the behavior of the market in which the Group operates and certain economic aspects, among other factors. Actual amounts may differ from these estimates. According to projections, the tax credit will be recovered according to the following schedule:

	Parent Company		Consolidated	
Recovery forecast	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
2026	265,801	259,432	319,096	304,446
2027	81,668	72,111	81,668	99,194
2028	59,898	55,060	59,898	82,143
2029	85,335	77,835	85,335	104,918
2030 and thereafter	47,466	43,056	47,467	70,138
Total	**540,168**	**507,494**	**593,464**	**660,839**
Deferred tax assets on temporary differences, recorded net in liabilities	540,168	507,494	593,464	507,494
Deferred tax assets on tax losses in subsidiaries	-	-	-	153,345

19.4. Uncertainties over the IRPJ and CSLL tax treatment

The Company has four discussions in the administrative stage with the Brazilian Federal Revenue referring to the disallowance for tax amortization of goodwill arising from acquisitions of companies in the amount of R$ 25,023, which, according to internal and external assessment of legal advisors, will probably be accepted in decisions of higher courts (probability of acceptance higher than 50%); for this reason, the Company did not record any IRPJ and CSLL liabilities in connection with these proceedings. The Company also has an uncertain position related to the treatment of investment subsidies, as disclosed in note 19.1(i).

20. Earnings per share

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of common shares outstanding during the period. Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potential common diluted shares.

The following table presents profit and share information used for calculating basic and diluted earnings per share:

	Parent Company / Consolidated	
Earnings per share items	**Sept/26**	**Sept/25**
Basic		
Profit for the period	991,742	991,943
Weighted average number of common shares	1,647,750	1,646,921
Basic earnings per share - R$	**0.60188**	**0.60230**
Diluted		
Profit for the period	991,742	991,943
Weighted average number of common shares adjusted for dilution effect	1,670,051	1,660,601
Diluted earnings per share - R$	**0.59384**	**0.59734**

21.Equity

(a) Share capital

At September 30, 2026, the fully paid-up capital amounted to R$ 4,750,000 (R$ 4,750,000 – Dec/25), represented by 1,752,367,344 book-entry registered common shares, with no par value, of which 1,315,656,615 were outstanding common shares (1,315,246,622 common shares – Dec/25).

Pursuant to the Company's bylaws, it is authorized to increase its capital up to the limit of 2,000,000,000 common shares, subject to the approval of the Board of Directors.

At September 30, 2026, the Company's ownership structure was as follows:

	Number of shares		Interest (%)	
Ownership interest	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Controlling shareholders	432,879,622	432,017,272	24.70	24.65
Shares outstanding	1,315,656,615	1,315,246,622	75.08	75.06
Treasury shares	3,831,107	5,103,450	0.22	0.29
Total	**1,752,367,344**	**1,752,367,344**	**100.00**	**100.00**

The ownership interest of the controlling shareholders is represented by the families Pipponzi, Pires Oliveira Dias and Galvão.

The change in the number of outstanding shares of the Company is as follows:

Changes	**Shares outstanding**
At January 1, 2025	1,290,335,615
(Purchase)/sale of restricted shares, net	24,911,007
At December 31, 2025	**1,315,246,622**
(Purchase)/sale of restricted shares, net	409,993
At September 30, 2026	**1,315,656,615**

At September 30, 2026, the Company's common shares were quoted at R$ 18.37 (closing quote) (R$ 23.45 – Dec/25).

(b) Treasury shares

The changes in treasury shares in the period ended September 30, 2026 are summarized below:

	Parent Company	
Changes in treasury shares	**Number of shares**	**Amount of shares**
At January 1, 2025	**6,012,572**	**124,991**
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, 1st tranche of the 2023 grant, and Performance Share 2020	(956,355)	(19,810)
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, and 1st tranche of the 2023 grant of the subsidiaries	(52,834)	(1,099)
Bonus shares	100,067	-
At December 31, 2025	**5,103,450**	**104,082**
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, 1st tranche of the 2023 grant, and Performance Share 2020	(1,204,337)	(24,316)
Shares delivered to executives related to the 3rd tranche of the 2021 grant, 2nd tranche of the 2022 grant, and 1st tranche of the 2023 grant of the subsidiaries	(68,006)	(1,387)
At September 30, 2026	**3,831,107**	**78,379**

At September 30, 2026, the market value of the treasury shares, having as reference the quotation of R$ 18.37 per share (R$ 23.45 - Dec/25), corresponds to R$ 70,377 (R$ 119,676 - Dec/25).

(c) Restricted share plan

Long-Term Incentive Program

Since March 2014, the Company offers its officers the Long-Term Incentive Program with Restricted Shares (the "Restricted Share Plan"), which aims to offer an opportunity to receive variable compensation provided that the officer remains for a predetermined period in the Company.

The maximum number of shares that may be delivered as a result of the exercise of the Plan is limited to 3% of the Company's Capital during the entire term of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary, will be equivalent to the average share price on B3 (weighted by the volume of trades) in the last thirty trading sessions preceding the grant.

As stated in the Restricted Share Plan, a portion of their annual variable compensation (profit-sharing) will be paid to the officer in cash and the remaining balance shall be paid only in Company shares ("incentive stock").

If the officer decides to use a portion or the total amount of the variable compensation paid in cash to buy Company shares ("own shares") on the stock exchange, the Company will offer the officer an equal number of shares purchased on the stock exchange.

At its discretion, the Company may grant to this officer more Company shares, using as reference the number of own shares acquired by the officer on the stock exchange.

The shares offered to the officer through the Restricted Share Plan may not be sold, assigned or transferred to third parties for a period of four years from the date of the grant. Every year, from the second, third and fourth anniversary of the grant date, the officers will acquire the right to receive a third of their restricted stock. The portion not exercised within the established terms and conditions will be automatically considered extinguished 7 years after the respective grant date. The fair value of the plan was R$ 172,707 at September 30, 2026 (R$ 172,488 - Dec/2025). The plans are measured at fair value on the grant date and are subsequently recognized in profit or loss on a pro rata basis until the plan vests. The exercise price of the options is equal to the market price of the shares on the grant date.

Performance shares

At a meeting of the Board of Directors on October 22, 2020, the granting of restricted shares was approved under the terms of the Restricted Share Granting Plan - Performance Shares ("Plan"), approved at the Extraordinary General Meeting of the Company held on September 15, 2020.

The purpose of the Plan is: (a) to foster the expansion, success and fulfillment of the corporate purposes of the Company and the companies under its control; (b) to align the interests of Beneficiaries with the interests of shareholders; and (c) to encourage Beneficiaries to stay in the Company or companies under its control. The Plan will be managed by the Board of Directors, and may have an advisory committee created or appointed by the Board of Directors to advise it in this respect. Beneficiaries will be chosen and elected by the Board of Directors at each new grant.

The maximum number of shares that may be delivered as a result of exercising the Plan is limited to 2% of the Company's Capital on the date of approval of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary will be equivalent to the average share price on B3 (weighted by the volume of trades) in the ninety trading sessions prior to January 1 of the year in which the grant occurs.

The definitive transfer of the Restricted Shares will be subject to the fulfillment of a four-year vesting period from the grant date and, at the end of the vesting period, the participant must be linked to the Company so that the grants are not canceled. Restricted Shares that have not yet completed the vesting period will become due and will be transferred to the holders, their estate or heirs in the event of death, permanent disability or retirement. The Plan provides that the liquidation must occur through the transfer of shares, however, in the event that the Company does not have treasury shares at the time of liquidation and / or upon inability to acquire shares on the market, the Board of Directors may choose to settle the delivery of the Restricted Shares in cash.

Changes in restricted shares

The changes in restricted shares are summarized below:

	Sept/26		Dec/25	
Changes in restricted shares	**Shares**	**Amount**	**Shares**	**Amount**
Opening balance at January 1	9,629,847	89,704	7,834,296	90,237
Granted shares for the period / year	1,996,201	29,159	2,704,673	27,880
Value of the shares at the delivery date	(1,272,343)	(26,804)	(909,122)	(28,413)
Closing balance	**10,353,705**	**92,059**	**9,629,847**	**89,704**

Position of the restricted share plan

Below is a breakdown of the assumptions that govern each grant plan:

Grants	**Grant date**	**Number of shares granted[(i)]**	**Date on which they will become exercisable**	**Period of restriction to share transfer**	**Fair value of shares on grant date[(i)]**
Long-Term Incentive Program					
2023 - 3rd tranche(i)	3/01/2023	566,160	2/28/2027	2/28/2026	R$ 23.90
2024 - 2nd tranche	3/01/2024	492,339	2/28/2027	2/28/2026	R$ 26.76
2024 - 3rd tranche	3/01/2024	492,243	2/28/2028	2/28/2027	R$ 26.76
2025 - 1st tranche	3/01/2025	628,650	2/28/2027	2/28/2026	R$ 22.15
2025 - 2nd tranche	3/01/2025	628,650	2/28/2028	2/28/2027	R$ 22.15
2025 - 3rd tranche	3/01/2025	628,753	2/28/2029	2/28/2029	R$ 22.15
2026 - 1st tranche	3/01/2026	400,510	2/28/2028	2/28/2028	R$ 23.38
2026 - 2nd tranche	3/01/2026	400,510	2/28/2029	2/28/2029	R$ 23.38
2026 - 3rd tranche	3/01/2026	400,594	2/28/2030	2/28/2030	R$ 23.38
Performance shares					
2021 - 1st tranche	1/01/2021	303,887	2/01/2025	1/01/2028	R$ 22.82
2022 - 1st tranche	1/01/2022	386,840	2/01/2026	1/01/2027	R$ 22.44
2023 - 1st tranche	1/01/2023	441,388	2/01/2027	1/01/2028	R$ 22.18
2024 - 1st tranche	1/01/2024	402,056	2/01/2028	1/01/2029	R$ 26.86
2025 - 1st tranche	1/01/2025	422,406	2/01/2029	1/01/2030	R$ 24.79

(i) After the application of the stock split effect, approved at the EGM held on September 15, 2020 and, on April 10, 2023 as a bonus, 1 (one) new share for every 25 (twenty-five) shares issued by the Company that were outstanding.

22.Net sales revenue

	Parent Company			
Breakdown of net revenue	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
Sales revenue	13,016,702	37,600,315	11,271,129	31,877,886
Service revenue	23,661	71,516	20,539	60,541
Gross sales revenue	**13,040,363**	**37,671,831**	**11,291,668**	**31,938,427**
Taxes on sales	(1,480,761)	(4,092,947)	(542,620)	(1,560,079)
Returns, rebates and other	(265,212)	(761,926)	(217,702)	(591,458)
Net sales revenue	**11,294,390**	**32,816,958**	**10,531,346**	**29,786,890**

	Consolidated			
Breakdown of net revenue	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
			Restated	Restated
Sales revenue	13,026,236	37,626,428	11,277,815	31,896,171
Service revenue	137,047	294,119	70,057	203,494
Gross sales revenue	**13,163,283**	**37,920,547**	**11,347,872**	**32,099,665**
Taxes on sales	(1,496,525)	(4,126,059)	(549,720)	(1,580,126)
Returns, rebates and other	(257,752)	(754,495)	(217,720)	(591,521)
Net sales revenue	**11,409,006**	**33,039,993**	**10,580,432**	**29,928,018**

23.Information on the nature of expenses recognized in the statement of income

The Group presented its statement of income using a classification based on the function of expenses. Information on the nature of these expenses is recorded in the statement of income as follows:

	Parent Company			
Nature of expenses	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
			Restated	Restated
Costs of inventories sold (Note 8)	(7,576,664)	(22,067,731)	(7,298,158)	(20,640,769)
Personnel expenses	(1,613,481)	(4,694,896)	(1,386,729)	(3,976,991)
Occupancy expenses [(i)]	(117,240)	(378,514)	(103,772)	(326,569)
Depreciation and amortization [(ii)]	(546,820)	(1,596,524)	(503,323)	(1,469,260)
Service provider expenses	(74,999)	(223,132)	(47,870)	(164,583)
Expenses on card operator fees	(192,217)	(559,199)	(171,039)	(483,613)
Others	(354,738)	(992,611)	(302,149)	(849,386)
Total	**(10,476,159)**	**(30,512,607)**	**(9,813,040)**	**(27,911,171)**

Classified in the statement of income as:

Function of expenses	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
Costs of sales and services	(7,574,006)	(22,061,500)	(7,295,917)	(20,637,728)
Selling	(2,514,688)	(7,337,955)	(2,154,159)	(6,217,471)
General and administrative	(387,465)	(1,113,152)	(362,964)	(1,055,972)
Total	**(10,476,159)**	**(30,512,607)**	**(9,813,040)**	**(27,911,171)**

	Consolidated			
Nature of expenses	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
			Restated	Restated
Costs of inventories sold (Note 8)	(7,583,276)	(22,086,721)	(7,304,488)	(20,657,772)
Personnel expenses	(1,651,421)	(4,770,121)	(1,404,445)	(4,030,272)
Occupancy expenses [(i)]	(115,770)	(374,651)	(102,507)	(323,730)
Depreciation and amortization [(ii)]	(561,479)	(1,618,763)	(506,704)	(1,477,999)
Service provider expenses	(110,308)	(298,978)	(68,697)	(226,067)
Expenses on card operator fees	(192,411)	(559,748)	(171,260)	(484,126)
Others	(361,757)	(1,004,698)	(304,497)	(857,357)
Total	**(10,576,422)**	**(30,713,680)**	**(9,862,598)**	**(28,057,323)**

Classified in the statement of income as:

Function of expenses	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
Costs of sales and services	(7,611,705)	(22,150,664)	(7,321,761)	(20,711,277)
Selling	(2,535,774)	(7,370,835)	(2,159,649)	(6,234,777)
General and administrative	(428,943)	(1,192,181)	(381,188)	(1,111,269)
Total	**(10,576,422)**	**(30,713,680)**	**(9,862,598)**	**(28,057,323)**

(i) These refer to expenses on property rental, condominium fees, electricity, water, communication and municipal real estate tax (IPTU).

(ii) Depreciation and amortization totaled R$ 1,596,525 in the nine-month period of 2026 (R$ 1,469,260 - Sept/25) for the Parent Company, of which R$ 1,361,311 (R$ 1,249,368 - Sept/25) refer to the Sales area, and R$ 235,214 (R$ 219,892 - Sept/25) to the Administrative area, and totaled R$ 1,615,086 (R$ 1,477,999 - Sept/25) for the Consolidated accounts, of which R$ 1,361,311 (R$ 1,249,368 - Sept/25) refer to the Sales area and R$ 253,775 (R$ 228,631 - Sept/25) to the Administrative area. These amounts are net of PIS and COFINS credits on the lease right of use, which allowed a reduction of expenses in the amount of R$ 49,007 (R$ 27,326 – Sept/25).

24. Other operating income or expenses, net

At September 30, 2026, other operating income or expenses totaled (R$ 202,688) (R$ 49,747 - Sept/25) for the Parent company and (R$ 202,330) (R$ 53,715 - Sept/25) for the Consolidated accounts. These amounts comprise non-recurring expenses and revenues, as presented below:

	Parent Company			
Nature of income / (expenses)	3rd Quarter/26	Sept/26	3rd Quarter/25	Sept/25
Discontinued operation 4Bio [(i)]	(419)	(203,002)	-	-
Gain on the acquisition of subsidiary – Stix [(ii)]	-	19,568	-	-
Corporate restructuring	-	-	(5)	(25,645)
Social investment	(1,381)	(6,890)	(2,991)	(9,093)
Donations	734	(2,909)	1,390	(7,279)
Write-off of fixed assets and intangible assets	540	(5,331)	3,162	3,720
Refund of ICMS on losses from prior periods	-	-	-	63,842
Tax refund for previous periods (ICMS / ICMS-ST / PIS and COFINS	-	14,908	2,813	4,161
INSS credits from 2018 to 2022	-	-	12,741	12,741
Excess losses on unsuitable products	-	-	-	(36,575)
Non-recurring reversals of provisions [(iii)]	-	13,680	43,300	43,300
Other tax income/expenses	(13,008)	(16,123)	-	250
Other	(2,968)	(16,589)	325	325
Total	**(16,502)**	**(202,688)**	**60,735**	**49,747**

	Consolidated			
Nature of income / (expenses)	3rd Quarter/26	Sept/26	3rd Quarter/25	Sept/25
			Restated	Restated
Discontinued operation 4Bio [(i)]	(419)	(203,002)	-	-
Gain on the acquisition of subsidiary – Stix [(ii)]	-	19,568	-	-
Corporate restructuring	-	-	(5)	(25,645)
Social investment	(1,381)	(6,890)	(2,991)	(9,093)
Donations	734	(2,909)	1,390	(7,279)
Write-off of fixed assets and intangible assets	540	(5,331)	3,162	3,720
Refund of ICMS on losses from prior periods	-	-	-	63,842
Tax refund for previous periods (ICMS / ICMS-ST / PIS and COFINS	-	14,908	2,813	4,161
INSS credits from 2018 to 2022	-	-	12,741	12,741
Excess losses on unsuitable products	-	-	-	(36,575)
Non-recurring reversals of provisions [(iii)]	-	13,680	43,300	43,300
Other tax income/expenses	(13,008)	(16,123)	-	250
Other	(2,987)	(16,231)	258	4,293
Total	**(16,521)**	**(202,330)**	**60,668**	**53,715**

(i) (i) As explained in Note 30.1
(ii) (i) As explained in Note 10.1
(iii) Reversal of the provision for contingent consideration payable to the former shareholders of ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil") for not achieving the goals established in the purchase and sale agreement.

25.Finance income (costs)

	Parent Company			
Finance income	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
Present value adjustment	130,321	375,651	109,140	280,605
Short-term investment yields	1,967	4,658	2,569	6,074
Monetary variations	22,924	54,826	7,367	12,012
Discounts obtained	284	1,574	237	994
Other income	1	2,160	-	-
Total finance income	**155,497**	**438,869**	**119,313**	**299,685**

Finance costs	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25**	**Sept/25**
Present value adjustment	(185,258)	(541,566)	(174,930)	(472,097)
Interest on leases(i)	(139,078)	(391,074)	(116,243)	(335,235)
Charges on debentures	(125,149)	(387,418)	(138,320)	(360,406)
Interest, charges and bank fees	(24,074)	(85,533)	(24,623)	(74,645)
Charges on borrowings	-	-	-	(52)
Interest on payables to subsidiary's shareholder	(568)	(1,629)	(535)	(1,407)
Monetary variations	(218)	(517)	-	-
Amortization of transaction costs	(1,891)	(6,024)	(2,324)	(7,154)
Total finance costs	**(476,236)**	**(1,413,761)**	**(456,975)**	**(1,250,996)**
Finance income (costs)	**(320,739)**	**(974,892)**	**(337,662)**	**(951,311)**

	Consolidated			
Finance income	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25 Restated**	**Sept/25 Restated**
Present value adjustment	130,321	376,923	109,140	280,605
Short-term investment yields	8,618	14,805	12,869	28,201
Monetary variations	23,140	55,137	7,429	12,168
Discounts obtained	295	1,627	244	1,027
Other income	119	2,267	242	498
Total finance income	**162,493**	**450,759**	**129,924**	**322,499**

Finance costs	**3rd Quarter/26**	**Sept/26**	**3rd Quarter/25 Restated**	**Sept/25 Restated**
Present value adjustment	(185,258)	(541,566)	(174,930)	(472,096)
Interest on leases[(i)]	(139,078)	(391,074)	(116,243)	(335,235)
Charges on debentures	(125,149)	(387,418)	(138,320)	(360,406)
Interest, charges and bank fees	(24,239)	(85,960)	(24,716)	(75,071)
Charges on borrowings	-	-	-	(52)
Interest on payables to subsidiary's shareholder	(568)	(1,629)	(535)	(1,407)
Monetary variations	(268)	(1,283)	(2)	(3)
Amortization of transaction costs	(1,891)	(6,024)	(2,325)	(7,154)
Discounts granted	(45)	(176)	(22)	(94)
Total finance costs	**(476,496)**	**(1,415,130)**	**(457,093)**	**(1,251,518)**
Finance income (costs)	**(314,003)**	**(964,371)**	**(327,169)**	**(929,019)**

(i) (i) Interest on leases is shown net of PIS and COFINS.

26.Financial instruments and risk management policy

26.1. Financial instruments by category

	Parent Company		Consolidated	
Financial instruments items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Assets				
At amortized cost				
Cash and cash equivalents (Note 5)	270,859	296,965	503,985	509,619
Trade receivables (Note 7)	3,231,396	2,757,988	3,372,755	3,400,585
Other current assets	1,587,363	689,044	1,547,131	743,571
Judicial deposits (Note 17)	68,318	66,196	68,344	301,319
Related parties	113,778	96,371	-	89,095
Subtotal	**5,271,714**	**3,906,564**	**5,492,215**	**5,044,189**
Measured at Fair Value Through Profit or Loss				
Held-to-maturity investments (Note 6)	28,922	28,112	123,210	19,120
Subtotal	**28,922**	**28,112**	**123,210**	**19,120**
Total assets	**5,300,636**	**3,934,676**	**5,615,425**	**5,063,309**
Liabilities				
Liabilities at fair value through profit or loss				
Suppliers - FIDC (Note 15)	-	-	253,375	228,549
Payables to subsidiary's shareholder	17,147	15,518	17,147	15,518
Subtotal	**17,147**	**15,518**	**270,522**	**244,067**
Other liabilities				
At amortized cost				
Suppliers	6,172,827	6,425,749	6,076,834	6,680,650
Borrowings (Note 16)	3,505,881	3,867,755	3,505,881	3,867,755
Other liabilities	504,904	483,977	653,566	578,055
Leases payable	5,325,644	4,959,231	5,326,752	4,966,312
Related parties	22,051	22,366	-	22,366
Subtotal	**15,531,307**	**15,759,078**	**15,563,033**	**16,115,138**
Total liabilities	**15,548,454**	**15,774,596**	**15,833,555**	**16,359,205**

26.2. Financial risk management

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group's risk management program focuses on the unpredictability of financial and operational markets and seeks to minimize potential adverse effects on the Group's financial performance.

The Board of Directors provides principles for overall risk management, as well as written policies covering specific areas, such as interest rate risk, credit risk, use of non-derivative financial instruments and investment of surplus cash.

(a) Market risk

Foreign exchange risk

The Company's assets and liabilities are mainly carried out in Brazilian reais (R$), and there is no risk due to exchange rate variations. During 2025, all foreign currency loans were fully repaid.

Interest rate risk

The Company's borrowings are pegged to the CDI plus bank spread. Financial investments are entered into based on the CDI variations, which does not result in higher interest rate risk since these variations are not significant. Management understands that there is a low risk of significant changes in profit or loss or in cash flows.

(b) Credit risk

Credit risk arises from financial assets, i.e. cash and cash equivalents, short-term investments and trade receivables. Cash and cash equivalents and short-term investments are maintained with sound financial institutions.

The risk ratings of the cash equivalents are in accordance with the main risk rating agencies, according to the table below:

	Parent Company		Consolidated	
Risk rating	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Rating - National scale				
brAAA	76,651	3,047	306,505	196,293
brAA+	433	12,196	1,721	14,285
brA	221	125	221	125
(*) n/a - Cash and automatic investments	193,554	281,597	195,538	298,916
Total - National scale	**270,859**	**296,965**	**503,985**	**509,619**

(*) Not applicable, since there is no risk rating for cash and automatic Investments.

The granting of credit on sales of goods follows a policy that aims at minimizing defaults. For the period ended September 30, 2026, credit sales represented 77% (74% in 2025) for the Parent Company and 77% (77% in 2025) for the Consolidated accounts, of which 71% (73% in 2025) for the Parent Company and 71% (64% in 2025) for the Consolidated accounts related to credit card sales which, based on the history of losses, posed an extremely low risk. The other 29% (27% in 2025) for the Parent Company and 29% (36% in 2025) for the Consolidated accounts refer substantially to credits from Medicine Benefit Programs ("PBMs") and special plans that pose a low risk, due to customer selectivity.

(c) Liquidity risk

The Group's management continuously monitors forecasts of the Company's liquidity requirements, in order to ensure that it has sufficient cash to meet operational needs. The Group invests its surplus cash in financial assets with appropriate maturities to provide the liquidity necessary to honor its obligations.

(d) Sensitivity analysis

The Company prepares a sensitivity analysis of financial instruments indexed to interest rates to which the Company is exposed.

According to Management's assessment, the most likely scenario considers a 0.50% reduction in the benchmark interest rate over the next six months and the resulting impacts on revenue and expenses. In addition, another scenario is presented to illustrate a 25% change in the risk variable under consideration (Scenario II), as shown below:

		Parent Company	
		Effect on profit or loss and equity	
Operation	**Notional amount**	**Scenario I (probable)**	**Scenario II - 25%**
Short-term investments - CDI	116,863	(1,461)	(1,096)
Revenue		**(1,461)**	**(1,096)**
Borrowings - CDI	3,505,881	43,824	32,868
Expense		**43,824**	**32,868**
Effect on profit or loss		**42,363**	**31,772**

		Consolidated	
		Effect on profit or loss and equity	
Operation	**Notional amount**	**Scenario I (probable)**	**Scenario II - 25%**
Short-term investments - CDI	319,197	(3,990)	(2,992)
Revenue		**(3,990)**	**(2,992)**
Borrowings - CDI	3,505,881	43,824	32,868
Expense		**43,824**	**32,868**
Effect on profit or loss		**39,834**	**29,876**

(e) Capital management

The Group's objective relating to capital management is to maintain the Group's investment capacity, thus allowing it to grow its business and provide proper returns for shareholders.

The Group has adopted a policy of not leveraging its capital structure with borrowings, except for long-term credit facilities of debentures at interest rates that are commensurate with the Group's profit levels.

Accordingly, this ratio corresponds to the net debt expressed as a percentage of total capital. The net debt, in turn, corresponds to total borrowings less cash and cash equivalents. The total capital is calculated through the sum of the equity, as shown in the individual and consolidated balance sheet, and the net debt, as presented below:

	Parent Company		Consolidated	
Capital management items	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Short- and long-term borrowings	3,505,881	3,867,755	3,505,881	3,867,755
(-) Cash and cash equivalents	(270,859)	(296,965)	(503,985)	(509,619)
Net debt	**3,235,022**	**3,570,790**	**3,001,896**	**3,358,136**
Equity attributable to the shareholders of the parent	7,551,491	7,322,129	7,551,491	7,322,129
Noncontrolling interests	-	-	-	13,839
Total equity	**7,551,491**	**7,322,129**	**7,551,491**	**7,335,968**
Total capital	**10,786,513**	**10,892,919**	**10,553,387**	**10,694,104**
Gearing ratio (%)	**29.99%**	**32.78%**	**28.44%**	**31.40%**

At September 30, 2026, the balance of lease liabilities for the Parent Company and Consolidated accounts amounted to R$ 5,325,644 and R$ 5,326,752 respectively. Considering the lease liability in the capital management calculation, the gearing ratio of the Company and the Group would be 53.13% for the Parent Company and 52.45% for the Consolidated accounts. Considering the balance of lease liabilities at the balance sheet dates in the capital management calculation, the gearing ratio of the Company and the Group would be as follows:

	Parent Company		Consolidated	
Adjusted net debt with lease liabilities	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**
Net debt	3,235,022	3,570,790	3,001,89(	3,358,136
Lease liabilities	5,325,644	4,959,231	5,326,75(	4,966,312
Adjusted net debt	**8,560,666**	**8,530,021**	**8,328,64**	**8,324,448**
Total equity	7,551,491	7,322,129	7,551,49	7,335,968
Total adjusted capital	**16,112,157**	**15,852,150**	**15,880,13**	**15,660,416**
Adjusted gearing ratio (%)	**53.13%**	**53.81%**	**52.45%**	**53.16%**

(f) Fair value estimation

The carrying values of financial investments in the balance sheet approximate their fair values since the remuneration rates are based on the CDI variation. The carrying values of trade receivables and payables are measured at amortized cost and are recorded at their original amount, less the provision for impairment and present value adjustment, when applicable. The carrying values are assumed to approximate their fair values, taking into consideration the realization of these balances and settlement terms not exceeding 60 days.

Borrowings are classified as financial liabilities not measured at fair value through profit or loss and are recognized using the amortized cost method, according to contractual conditions. The fair values of these instruments are considered substantially equivalent to their respective carrying amounts, since they refer to floating-rate financial instruments linked to the CDI, plus spreads consistent with prevailing market rates. Any differences between the estimated fair values and the carrying amounts are considered immaterial.

At September 30, 2026, the Group had no material assets and liabilities measured at fair value at Level 2 in the fair value hierarchy.

The following table presents the balances in Level 1 instruments for the period ended September 30, 2026:

	Parent Company	
Assets	**Sept/26**	**Dec/25**
RD Fundo de Investimento em Direitos Creditórios Corporativos	28,922	28,112
Total	**28,922**	**28,112**

	Consolidated	
Liabilities	**Sept/26**	**Dec/25**
Suppliers - FIDC	253,375	228,549
Total	**253,375**	**228,549**

The following table presents the changes in Level 3 instruments for the period ended September 30, 2026:

	Parent Company/Consolidated	
	Payables to subsidiary's shareholder	
Changes in payables to subsidiary's shareholder	**Sept/26**	**Dec/25**
Balance at January 1	15,518	13,573
Expenses recognized in the statement of income	1,629	1,945
Closing balance	17,147	15,518
Total expenses for the period recognized in the statement of income	**1,629**	**1,945**
Changes in unrealized expenses for the period included in the statement of income	**1,629**	**1,945**

27.Transactions with related parties

		Parent Company		Consolidated		Parent Company		Consolidated	
		Assets				Transacted amount			
Related parties	**Relationship**	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**	**Sept/26**	**Sept/25**	**Sept/26**	**Sept/25**
Current assets									
Receivables									
Special plans [i]									
4Bio Medicamentos Ltda.	Subsidiary	-	37	-	-	157	419	-	-
Regimar Comercial S.A.	Shareholder/Family	-	22	-	22	12	79	12	79
Impulso	Subsidiary	7	4	-	-	36	40	-	-
Amplisoftware Tecnologia Ltda.	Subsidiary	1	1	-	-	-	-	-	-
Labi Exames S.A.	Associate	-	3	-	3	-	-	-	-
Heliomar Ltda.	Shareholder/Board Member	-	-	-	-	16	12	16	12
Healthbit Performasys Tecnologia	Subsidiary	13	-	-	-	-	-	-	-
Advances to suppliers									
Cfly Consultoria e Gestão Empresarial Ltda.[ii]	Shareholder/Family	262	2,337	262	-	7,790	3,948	7,790	3,948
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados[iii]	Shareholder/Family	-	-	-	-	54	158	54	158
Other receivables									
Rodrigo Wright Pipponzi (Mol Impacto)[vi]	Shareholder/Family	-	165	-	165	874	357	874	357
Subtotal [a]		**283**	**2,569**	**262**	**190**	**8,939**	**5,013**	**8,746**	**4,554**
Other receivables									
Stix Fidelidade e Inteligência S.A. [vii]	Subsidiary	113,372	89,095	-	89,095	43,227	54,298	-	54,298
Impulso [xi]	Subsidiary	378	4,868	-	-	10,815	8,980	-	-
ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil")[ix]	Subsidiary	28	13	-	-	115	133	-	-
4Bio Medicamentos S.A. [iv]	Subsidiary	-	2,395	-	-	7,571	-	-	-
Subtotal		**113,778**	**96,371**	**-**	**89,095**	**61,728**	**63,411**	**-**	**54,298**
Total current assets		**113,778**	**96,371**	**-**	**89,095**	**61,728**	**63,411**	**-**	**54,298**
Non-current assets									
Loans									
Healthbit Performasys Tecnologia [iv]	Subsidiary	-	-	-	-	-	1	-	-
Total non-current assets		**-**	**-**	**-**	**-**	**-**	**1**	**-**	**-**
Total receivables from related parties		**114,061**	**98,940**	**262**	**89,285**	**70,667**	**68,425**	**8,746**	**58,852**

Transactions with related parties consist of transactions with the Company's shareholders and persons connected to them:

		Parent Company		Consolidated		Parent Company		Consolidated	
		Liabilities				Transacted amount			
Related parties	**Relationship**	**Sept/26**	**Dec/25**	**Sept/26**	**Dec/25**	**Sept/26**	**Sept/25**	**Sept/26**	**Sept/25**
Current liabilities									
Related parties									
Stix Fidelidade e Inteligência S.A. (vii)	Subsidiary	22,051	22,366	-	22,366	91,916	87,070	-	87,070
Subtotal		**22,051**	**22,366**	**-**	**22,366**	**91,916**	**87,070**	**-**	**87,070**
Payables									
Rentals (v)									
Heliomar Ltda.	Shareholder/Board Member	32	-	32	-	228	365	228	365
Antonio Carlos Pipponzi	Shareholder/Board Member	13	12	13	12	100	107	100	107
Rosalia Pipponzi Raia	Shareholder/Board Member	13	12	13	12	100	107	100	107
Cristiana Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	33	36	33	36
André Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	33	36	33	36
Marta Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	33	36	33	36
Obligation the acquisition of investees (xiii)									
ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil")	Director(s)	-	13,545	-	-	-	2,160	-	-
SafePill Comércio Varejista de Medicamentos Manipulados Ltda. ("Dose Certa + Cuidado")	Director(s)	-	-	-	-	-	20,790	-	-
Subtotal (a)		**70**	**13,581**	**70**	**36**	**527**	**23,637**	**527**	**687**
Service providers									
Impulso (xi)	Subsidiary	-	45	-	-	10,666	8,731	-	-
Amplisoftware Tecnologia Ltda. (x)	Subsidiary	435	338	-	-	4,962	5,929	-	-
Labi Exames S.A. (xii)	Associate	-	-	-	-	-	145	-	145
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados (iii)	Shareholder/Family	648	532	648	532	3,510	3,557	3,510	3,557
Kymberg (xiv)	Subsidiary	9	258	-	-	578	-	-	-
Rodrigo Wright Pipponzi (Mol Impacto) (vi)	Shareholder/Family	-	-	-	-	22,052	19,223	22,052	19,223
Healthbit Performasys Tecnologia (iv)	Subsidiary	432	119	-	-	2,237	1,624	-	-
Healthbit Serviços Médicos Ltda. (iv)	Subsidiary	343	252	-	-	1,647	1,039	-	-
4Bio Medicamentos Ltda. (iv)	Subsidiary	-	63	-	-	246	60,147	-	-
Associação Obra do Berço(xv)	Shareholder/Family	-	-	-	-	80	261	80	261
Cfly Consultoria e Gestão Empresarial Ltda. (ii)	Family	-	3,228	-	3,228	6,350	7,662	6,350	7,662
Subtotal (a)		**1,867**	**4,835**	**648**	**3,760**	**52,328**	**108,318**	**31,992**	**30,848**
Total payables to related parties		**23,988**	**40,782**	**718**	**26,162**	**144,771**	**219,025**	**32,519**	**118,605**

(a) The balances of receivables and payables with related parties, arising from commercial transactions between the Company and its Related Parties, are allocated by function, with transactions with the same characteristics carried out with third parties.

Transactions with related parties, basically purchases and sales of products, were carried out at prices, terms and conditions usual in the market.

(i) Sales made by agreements whose transactions are carried out under commercial conditions equivalent to those adopted with other companies.

(ii) Services of aircraft operation owned by Raia Drogasil S.A., which will pay the operator a monthly remuneration for the services of operational advisory, compliance, finance, maintenance coordination and maintenance technical control.

(iii) Transaction related to legal advisory.

(iv) Balance related to intermediation of commissions on Raia Drogasil S.A. referrals.

(v) Transactions related to rental of commercial properties for the implementation of pharmacies.

(vi) The balances and transactions relate to service agreements for the development, creation and production of marketing materials for the institutional sales area, and the design of the Company's internal magazine.

(vii) Transactions related to trade receivables and suppliers referring to the Stix points program.

(viii) Loan transaction with subsidiary ZTO Tecnologia e Serviços de Informação na Internet Ltda - Manipulaê, which is updated by CDI + 1.45% p.a. The transaction was completed in 2024.

(ix) Provision of services related to health programs.

(x) The balances and transactions refer to the provision of services related to implementation of electronic medical records for physicians and systems in pharmacies so that customers are able to schedule exams and consultations in pharmacies.

(xi) Represents the reimbursement of the sharing of costs or expenses, such as consulting services and software licensing.

(xii) Provision of services related to tests.

(xiii) Obligation arising from the acquisition of the investee, with the amount classified as Accounts payable for acquisition of subsidiaries in the balance sheet.

(xiv) Transactions related to the purchase of Company brands medications.

(xv) Transactions relating to social projects.

We also inform that there are no additional transactions other than the amounts presented above and that the category of the related parties corresponds to the entity's key management personnel.

(b) Key management compensation

Key management includes the Officers, Directors and members of the Supervisory Board. The compensation paid or payable for services rendered is as follows:

	Parent Company		Consolidated	
Compensation items	**Sept/26**	**Sept/25**	**Sept/26**	**Sept/25**
Share-based payment	30,672	24,780	30,672	24,976
Bonuses and social charges	16,014	8,999	20,792	10,390
Subtotal bonuses and social charges	**46,686**	**33,779**	**51,464**	**35,366**
Fees and social charges	26,907	23,692	26,907	26,882
Fringe benefits	77	444	77	444
Total	**73,670**	**57,915**	**78,448**	**62,692**

The Company applied the requirements of NBC TG 05 (R3) - Related-Party Disclosures and also considered the guidance in CVM Circular Letter SNC/SEP 1/2021, observing qualitative aspects of related-party transaction, and concluded that there are no material impacts that require disclosure of additional information in the interim financial information.

28.Insurance coverage

The Group has adopted a policy of taking out insurance coverage at amounts deemed sufficient to cover any losses on assets or civil liability attributed to it taking into consideration the nature of its activities and the guidance of its insurance consultants.

Insurance coverage amounts to R$ 1,708,958,650, considering Operational Risks, Civil Liability, D&O, Cyber Risk, Transportation, Fleet, Aircraft and Environmental policies.

29.Non-cash transactions

At September 30, 2026, the Group's main non-transactions were:

a) part of the compensation of key management personnel associated with the restricted share plan (Note 27);
b) the installment purchase of fixed assets items in the amount of R$ 25,522 (R$ 25,576 - Dec/25).
c) Recognition of lease liability with a balancing item in right-of-use asset, with additions of new agreements in the amount of R$ 520,751 (R$ 478,970 - Sept/25) for the Parent Company and R$ 522,148 (R$ 480,984 – Sept/25) for the Consolidated accounts, remeasurements of R$ 606,690 (R$ 676,247 - Sept/25) for the Parent Company and R$ 606,908 (R$ 676,843 – Sept/25) for the Consolidated accounts, and terminations of agreements in the amount of R$ (18,132) ((R$ 31,112) Sept/25) for the Parent Company and R$ (18,132) ((R$ 31,112) – Sept/25) for the Consolidated accounts.
d) Recognition of impairment loss on the investment in 4Bio in the amount of R$ 203,002 (Note 30).

30.Discontinued operations – Sale of 4Bio

30.1 Sale of investee – 4Bio

On May 4, 2026, the Company and Health Ventures S.A., a direct subsidiary of Profarma Distribuidora de Produtos Farmacêuticos S.A., executed the closing agreement for the sale of 4Bio, following the fulfillment of all suspensive conditions set forth in the Share Purchase and Sale Agreement and Other Covenants. On that date, the Company received R$ 100,000 in cash, representing the up-front portion of the transaction, and became entitled to receive the remaining amount (note 1.1) The balance receivable for the disposal is recorded in the line item of other receivables in the amount of R$ 697,408 net of the portion already received in cash.

As a result of the transaction, the Company has no longer consolidated the assets, liabilities, revenues and expenses of the investee since the date of loss of control (May 4, 2026), in conformity with the requirements of CPC 36 (R3) / IFRS 10 – Consolidated Financial Statements.

As of September 30, 2026, the Company measured the fair value of the asset held for sale as a result of this measurement and recorded an expense of R$ 203,002 due to an impairment loss:

Fair value of the transaction	Sept/26
Amount receivable in cash [1]	500,000
Amount received in cash upon approval [1]	100,000
Amount receivable related to working capital [2]	31,928
Amount received related to working capital [2]	41,411
Judicial deposit (DIFAL) [3]	120,461
Selling price	**793,800**
Net assets	983,193
Goodwill on future profitability	12,907
Surplus values	702
Total investments (Note 10)	**996,802**
Impairment loss	**(203,002)**
Update of other receivables	38,487
Updated gain/(loss)	**(164,515)**
Impact on income tax - 34%	55,935
Impact on RD Saúde's result	**(108,580)**

[1] Six fixed installments totaling R$ 100,000, with one installment due upon completion of the transaction and five annual installments adjusted by the CDI.
[2] Payment of working capital to RD Saúde in the estimated amount of R$ 73,339.
[3] R$ 120,461 net of success fee of R$ 6,836 in connection with a judicial deposit related to ICMS-DIFAL recorded in 4Bio, to which the Company is entitled to receive payment as soon as the lawsuit is enforced.

30.2. Breakdown of discontinued operation amounts

The results of discontinued operations, which include the operations of the former subsidiary 4Bio, for the periods ended September 30, 2026, and 2025 are presented below:

	Sept/26[1]	3rd Quarter/25	Sept/25
Net sales revenue	1,042,014	684,484	2,218,950
Cost of sales and services	(968,837)	(627,329)	(2,035,734)
Gross profit	**73,177**	**57,155**	**183,216**
Operating (expenses) income			
Selling	(40,062)	(30,160)	(93,682)
General and administrative	(14,283)	(11,304)	(32,775)
Other operating income/(expenses)	(7,265)	55,997	67,800
	(61,610)	**(14,533)**	**(58,657)**
Operating profit before finance results	**11,567**	**71,688**	**124,559**
Finance income (costs)			
Finance income	38,351	26,024	72,315
Finance costs	(29,957)	(5,516)	(46,706)
	8,394	**20,508**	**25,609**
Profit before income tax and social contribution	**19,961**	**92,196**	**150,168**
Income tax and social contribution			
Current	-	12	25,095
Deferred	-	-	(1,547)
	-	12	23,548
Profit for the period	**19,961**	**92,208**	**173,716**

The net cash flows from the discontinued operation are presented below:

	Sept/26[1]	Sept/25
Operating activities	(20,052)	162,767
Investing activities	(1,928)	171,302
Financing activities	(893)	(90,838)
Net cash generated (used)	**(22,873)**	**243,231**

[1] The accumulated balance includes the four-month period (January to April) related to the sale of 4Bio completed on May 4, 2026.

Deloitte Touche Tohmatsu
Av. Dr. Chucri Zaidan, 1.240 -
4º ao 12º andares - Golden Tower
04711-130 - São Paulo - SP
Brasil

Tel.: + 55 (11) 5186-1000
Fax: + 55 (11) 5181-2911
www.deloitte.com.br

(Convenience Translation into English from the Original Previously Issued in Portuguese)

REPORT ON REVIEW OF INDIVIDUAL AND CONSOLIDATED INTERIM FINANCIAL INFORMATION

To the Shareholders and Management of
Raia Drogasil S.A.

Introduction

We have reviewed the individual and consolidated interim financial information of Raia Drogasil S.A. ("Company"), included in the Quarterly Interim Financial Information Form (ITR), for the quarter ended September 30, 2026, which comprises the balance sheet as at September 30, 2026, and the related statements of profit or loss for the three- and nine-month periods then ended, and changes in shareholders' equity and cash flows for the nine-month period then ended, including the accompanying explanatory notes.

The Company's Management is responsible for the preparation of the interim separate and consolidated financial information in accordance with CPC 21 (R1) – Interim Financial Reporting and IAS 34 – Interim Financial Reporting, as well as for the presentation of such information in conformity with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information Report (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and international standards on review of interim financial information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the individual and consolidated interim financial information included in the aforementioned Quarterly Information has not been prepared, in all material respects, in accordance with e with technical pronouncement CPC 21 (R1) and international standard IAS 34, applicable to the preparation of Quarterly Information (ITR), and presented in compliance with the rules issued by the CVM.

THIS DOCUMENT MUST BE DESTROYED OR RETURNED TO DELOITTE TOUCHE TOHMATSU AUDITORES INDEPENDENTES LTDA.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see www.deloitte.com/about to learn more.

Deloitte is a leading global provider of audit and assurance, consulting, financial advisory, risk advisory, tax and related services. Our global network of member firms and related entities in more than 150 countries and territories (collectively, the "Deloitte organization") serves four out of five Fortune Global 500® companies. Learn how Deloitte's approximately 460,000 people make an impact that matters at www.deloitte.com.

AND IT MUST NOT BE REPRODUCED OR DISTRIBUTED IN ANY FORM WITHOUT PERMISSION
© 2026. For information, contact Deloitte Global.

Deloitte Touche Tohmatsu
Av. Dr. Chucri Zaidan, 1.240 -
4º ao 12º andares - Golden Tower
04711-130 - São Paulo - SP
Brasil

Tel.: + 55 (11) 5186-1000
Fax: + 55 (11) 5181-2911
www.deloitte.com.br

Other matters

Statements of value added

The aforementioned Quarterly Information includes the individual and consolidated Statements of Value Added (SVA) for the nine-month period ended September 30, 2026, which was prepared under the responsibility of the Company's Management and presented as supplementary information for the purposes of International Accounting Standard IAS 34. These statements were subject to review procedures performed together with the review of the Quarterly Information, with the objective of concluding whether they are reconciled with the interim financial information and the accounting records, as applicable, and whether their form and content are in accordance with the criteria defined technical pronouncement CPC 09 (R1) - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that these statements were not prepared, in all material respects, in accordance with the criteria defined in that standard and presented consistently with respect to the individual and consolidated interim financial information taken as a whole.

The accompanying individual and consolidated interim financial information has been translated into English for the convenience of readers outside Brazil.

São Paulo, November 3, 2026

DELOITTE TOUCHE TOHMATSU
Auditores Independentes Ltda.

Natacha Rodrigues dos Santos
Engagement Partner

THIS DOCUMENT MUST BE DESTROYED OR RETURNED TO DELOITTE TOUCHE TOHMATSU AUDITORES INDEPENDENTES LTDA.
AND IT MUST NOT BE REPRODUCED OR DISTRIBUTED IN ANY FORM WITHOUT PERMISSION

© 2026. For information, contact Deloitte Global.

In this section, pursuant to CVM Resolution 80/2022, we compare the pharmacies opening projections for the Company with the data on pharmacies openings actually conducted every year.

On July 28, 2016, we revised the prior projection of 165 openings in 2016 and 195 openings in 2017 to 200 pharmacies openings for both years. On October 27, 2021, we revised the prior projection of 240 openings in 2022 to 260 openings. On October 31, 2022, we revised the prior projection for the period from 2023 to 2025 from 240 openings per year to 260 openings per year. On November 8, 2023, we revised the prior projection of 260 gross openings per year in 2023, 2024 and 2025 to 270 openings in 2023 and between 280 and 300 gross openings per year for 2024 and 2025. On November 29, 2024, we revised the prior projection of 280 to 300 gross openings per year to 330 to 350 gross openings per year for 2025. For 2026, the Company projected gross openings between 330 and 350 units, according to the material fact notice published on December 1, 2025.

YEAR	PRIOR PROJECTION	CURRENT PROJECTION	ACTUAL ACCUMULATED
2016	165 openings	200 openings	212 openings
2017	195 openings	200 openings	210 openings
2018	-	240 openings	240 openings
2019	-	240 openings	240 openings
2020	-	240 openings	240 openings
2021	-	240 openings	240 openings
2022	240 openings	260 openings	260 openings
2023	260 openings	270 openings	270 openings
2024	260 openings	Between 280 and 300 openings	300 openings
2025	Between 280 and 300 openings	Between 330 and 350 openings	330 openings
2026	-	Between 330 and 350 openings	236 openings

To the Board of Directors and Shareholders

Raia Drogasil S.A.

The Company's Supervisory Board, in exercising its duties and legal responsibilities, has examined the Interim Financial Information for the nine-month period ended September 30, 2026 and, based on the examinations performed and on clarifications provided by Management, and also considering the favorable Report on Special Review without exceptions, issued by the independent auditor Deloitte Touche Tohmatsu, the Supervisory Board members concluded that the documents above are fairly presented, in all material respects.

São Paulo, November 3, 2026.

Paulo Sérgio Buzaid Tohmé
Supervisory Board Member

Gilberto Lerio
Supervisory Board Member

Adeildo Paulino
Supervisory Board Member

Guilherme Bottrel Pereira Tostes
Supervisory Board Member

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the Interim Financial Information for the nine-month period ended September 30, 2026.

São Paulo, November 3, 2026.

Renato Cepollina Raduan
CEO

Marcello De Zagottis
COO

Antonio Carlos Coelho
Financial and Administrative Vice President

Melissa Teixeira Cabral
Pharmacy Operations Vice President

Fernando Kozel Varela
Digital Transformation Vice President

Juliana Lopes Marques Paixão
Commercial Vice President

Erika Vanessa do Amaral Petri
People, Culture and Sustainability Vice President

Bruno Wright Pipponzi
Health Business Vice President

Afonso Celso Florentino de Oliveira
Controlling and Technical Officer
CRC 1MG071304/O-7 'T' SP

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the conclusions expressed in the favorable Auditor's Report without exceptions issued by the independent auditors for the nine-month period ended September 30, 2026.

São Paulo, November 3, 2026.

Renato Cepollina Raduan
CEO

Marcello De Zagottis
COO

Antonio Carlos Coelho
Financial and Administrative Vice President

Melissa Teixeira Cabral
Pharmacy Operations Vice President

Fernando Kozel Varela
Digital Transformation Vice President

Juliana Lopes Marques Paixão
Commercial Vice President

Erika Vanessa do Amaral Petri
People, Culture and Sustainability Vice President

Bruno Wright Pipponzi
Health Business Vice President

Afonso Celso Florentino de Oliveira
Controlling and Technical Officer
CRC 1MG071304/O-7 'T' SP